

# Efficacy of Quadrivalent HPV Vaccine against HPV Infection

New England Journal of Medicine

364, 401-411

DOI: [10.1056/nejmoa0909537](https://doi.org/10.1056/nejmoa0909537)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Review of Gardasil. Journal of Vaccines & Vaccination, 2010, 01, .	0.3	22
3	Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact. Expert Review of Anti-Infective Therapy, 2011, 9, 627-639.	2.0	15
4	Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. Journal of Clinical Oncology, 2011, 29, 4294-4301.	0.8	3,060
5	Office Immunization. Primary Care - Clinics in Office Practice, 2011, 38, 729-745.	0.7	1
6	Adult Vaccination. Primary Care - Clinics in Office Practice, 2011, 38, 611-632.	0.7	3
8	Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine. Drugs, 2011, 71, 591-602.	4.9	23
9	Weighing the Benefits and Costs of HPV Vaccination of Young Men. New England Journal of Medicine, 2011, 364, 393-395.	13.9	36
10	Update on diagnosis, treatment, and prevention of genital human papillomavirus manifestations. Osteopathic Family Physician, 2011, 3, 106-111.	0.2	1
12	The Efficacy and Safety of the Quadrivalent Human Papillomavirus 6/11/16/18 Vaccine Gardasil. Journal of Adolescent Health, 2011, 49, 467-475.	1.2	50
13	The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine, 2011, 29, 9112-9122.	1.7	58
14	Economic burden of HPV-related cancers in France. Vaccine, 2011, 29, 5245-5249.	1.7	29
15	Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology, The, 2011, 12, 862-870.	5.1	168
16	Infections À papillomavirus humains (HPV) des voies aëro-digestives supérieures (VADS). Revue Francophone Des Laboratoires, 2011, 2011, 65-75.	0.0	3
17	Genital infection with HPV in men: research into practice. Lancet, The, 2011, 377, 881-883.	6.3	7
18	Male circumcision for prevention of oncogenic HPV infection. Lancet, The, 2011, 378, 314-315.	6.3	4
19	Épidémiologie du cancer de l'anus. Cancéro Digest, 2011, , .	0.0	1
20	Role and uptake of human papillomavirus vaccine in adolescent health in the United States. Adolescent Health, Medicine and Therapeutics, 2011, 2011, 63.	0.7	7
21	Small Molecule Inhibitors of Human Papillomavirus Protein - Protein Interactions. The Open Virology Journal, 2011, 5, 80-95.	1.8	62

#	ARTICLE	IF	CITATIONS
22	Safety of adjuvanted pandemic influenza A (H1N1) 2009 vaccines. <i>BMJ: British Medical Journal</i> , 2011, 343, d4159-d4159.	2.4	3
23	Update on childhood and adolescent immunizations. <i>Current Opinion in Pediatrics</i> , 2011, 23, 470-481.	1.0	7
24	Feasibility of Incorporating Self-Collected Rectal Swabs Into a Community Venue-Based Survey to Measure the Prevalence of HPV Infection in Men Who Have Sex With Men. <i>Sexually Transmitted Diseases</i> , 2011, 38, 964-969.	0.8	22
25	Human papillomavirus, cancer and vaccination. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 297-302.	1.5	20
26	Highlights of the 27th International Papillomavirus Conference and Clinical Workshop: part 1. <i>Future Virology</i> , 2011, 6, 1389-1396.	0.9	3
27	The role of human papillomavirus on sperm function. <i>Current Opinion in Obstetrics and Gynecology</i> , 2011, 23, 232-237.	0.9	38
28	An update on immunizations before and after transplantation in the pediatric solid organ transplant recipient. <i>Pediatric Transplantation</i> , 2011, 15, 770-777.	0.5	32
29	Aumento de la incidencia de c�ncer anal y poblaci3n de riesgo. <i>Piel</i> , 2011, 26, 365-366.	0.0	0
30	HPV: va-t-on vers une vaccination des gar�sons ?. <i>Option/Bio</i> , 2011, 22, 4.	0.0	0
31	Gardasil�, HPV vaccination: Surveillance of vaccine usage and adherence in a military population. <i>Gynecologic Oncology</i> , 2011, 123, 272-277.	0.6	18
32	The role of HPV in head and neck cancer and review of the HPV vaccine. <i>Preventive Medicine</i> , 2011, 53, S5-S11.	1.6	216
33	Genital HPV infection and related lesions in men. <i>Preventive Medicine</i> , 2011, 53, S36-S41.	1.6	90
34	Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. <i>Preventive Medicine</i> , 2011, 53, S12-S21.	1.6	201
35	Genital Condylomata Are Not the Human Papilloma Virus Male Infection Burden. <i>European Urology</i> , 2011, 60, 268-269.	0.9	4
37	Incidence and Human Papillomavirus (HPV) Type Distribution of Genital Warts in a Multinational Cohort of Men: The HPV in Men Study. <i>Journal of Infectious Diseases</i> , 2011, 204, 1886-1892.	1.9	66
38	Head and neck cancer: effective prevention in youth and predictive diagnostics for personalised treatment strategies according to biological differences. <i>EPMA Journal</i> , 2011, 2, 241-249.	3.3	15
39	Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. <i>Infectious Agents and Cancer</i> , 2011, 6, 11.	1.2	35
40	High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: A long-term followup study in a Danish cohort. <i>Arthritis and Rheumatism</i> , 2011, 63, 3032-3037.	6.7	108

#	ARTICLE	IF	CITATIONS
41	Acceptance on the move: Public reaction to shifting vaccination realities. <i>Hum Vaccin</i> , 2011, 7, 1261-1270.	2.4	32
42	HPV Vaccine against HPV Infection and Disease in Males. <i>New England Journal of Medicine</i> , 2011, 364, 2163-2165.	13.9	5
43	Rethinking the Head and Neck Cancer Population. <i>Clinical Journal of Oncology Nursing</i> , 2011, 15, 165-170.	0.3	8
44	Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. <i>BMJ: British Medical Journal</i> , 2011, 343, d5775-d5775.	2.4	102
45	HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia. <i>New England Journal of Medicine</i> , 2011, 365, 1576-1585.	13.9	810
46	Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. <i>Hum Vaccin</i> , 2011, 7, 768-775.	2.4	31
47	Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity. <i>Journal of Infectious Diseases</i> , 2011, 204, 372-376.	1.9	110
48	Updates on Human Papillomavirus and Genital Warts and Counseling Messages From the 2010 Sexually Transmitted Diseases Treatment Guidelines. <i>Clinical Infectious Diseases</i> , 2011, 53, S143-S152.	2.9	39
49	Serum Antibody Response Following Genital HPV Infection in Young Men. <i>Journal of Infectious Diseases</i> , 2011, 204, 209-216.	1.9	55
50	Human papilloma virus vaccines: Current scenario. <i>Indian Journal of Sexually Transmitted Diseases and AIDS</i> , 2011, 32, 75.	0.6	27
51	HPV-associated Oropharyngeal Cancers—Are They Preventable?. <i>Cancer Prevention Research</i> , 2011, 4, 1346-1349.	0.7	37
52	The Prevalence of Genital HPV and Factors Associated With Oncogenic HPV Among Men Having Sex With Men and Men Having Sex With Women and Men: The HIM Study. <i>Sexually Transmitted Diseases</i> , 2011, 38, 932-940.	0.8	56
53	Population Effectiveness, Not Efficacy, Should Decide Who Gets Vaccinated Against Human Papillomavirus via Publicly Funded Programs. <i>Journal of Infectious Diseases</i> , 2011, 204, 335-337.	1.9	17
54	New Approaches to Immunotherapy for HPV Associated Cancers. <i>Cancers</i> , 2011, 3, 3461-3495.	1.7	33
55	Male Human Papillomavirus Prevalence and Association With Condom Use in Brazil, Mexico, and the United States. <i>Journal of Infectious Diseases</i> , 2012, 205, 1287-1293.	1.9	30
56	How to Inform: Comparing Written and Video Education Interventions to Increase Human Papillomavirus Knowledge and Vaccination Intentions in Young Adults. <i>Journal of American College Health</i> , 2012, 60, 316-322.	0.8	57
57	Multiple Human Papillomavirus Infections and Type Competition in Men. <i>Journal of Infectious Diseases</i> , 2012, 205, 72-81.	1.9	29
58	Vaccination against sexually transmitted infections. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 66-72.	1.3	17

#	ARTICLE	IF	CITATIONS
60	Human papillomavirus vaccine and men. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 86-91.	1.3	27
61	HPV. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 671-680.	0.6	37
62	Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old. <i>Vaccine Journal</i> , 2012, 19, 261-267.	3.2	90
64	Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men. <i>Cancer Research</i> , 2012, 72, 676-685.	0.4	57
65	Evaluation of the HPV 18 antibody response in Gardasil <sup>®</sup> vaccinees after 48 mo using a pseudovirion neutralization assay. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 431-434.	1.4	12
66	Mother-Infant Transfer of Anti-Human Papillomavirus (HPV) Antibodies following Vaccination with the Quadrivalent HPV (Type 6/11/16/18) Virus-Like Particle Vaccine. <i>Vaccine Journal</i> , 2012, 19, 881-885.	3.2	21
67	Antibody Breadth and Protective Efficacy Are Increased by Vaccination with Computationally Optimized Hemagglutinin but Not with Polyvalent Hemagglutinin-Based H5N1 Virus-Like Particle Vaccines. <i>Vaccine Journal</i> , 2012, 19, 128-139.	3.2	68
68	Significant publications on infectious diseases pharmacotherapy in 2011. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1671-1681.	0.5	11
69	Genital warts in men: a large population-based cross-sectional survey of Danish men. <i>Sexually Transmitted Infections</i> , 2012, 88, 640-644.	0.8	18
70	Prevalence of Oral HPV Infection in the United States, 2009-2010. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 693.	3.8	875
71	Linear Epidermal Nevus of the Oral Cavity: A Rare Diagnosis. <i>Case Reports in Medicine</i> , 2012, 2012, 1-3.	0.3	3
72	Prevention of Recurrent High-Grade Anal Neoplasia With Quadrivalent Human Papillomavirus Vaccination of Men Who Have Sex With Men: A Nonconcurrent Cohort Study. <i>Clinical Infectious Diseases</i> , 2012, 54, 891-898.	2.9	164
73	Impact of Pap Test Compliance and Cervical Cancer Screening Intervals on Human Papillomavirus Vaccine Acceptance. <i>Journal of Lower Genital Tract Disease</i> , 2012, 16, 39-44.	0.9	3
74	Acceptance and Compliance With Postpartum Human Papillomavirus Vaccination. <i>Obstetrics and Gynecology</i> , 2012, 120, 771-782.	1.2	24
75	Rates and Determinants of Oral Human Papillomavirus Infection in Young Men. <i>Sexually Transmitted Diseases</i> , 2012, 39, 860-867.	0.8	98
76	Prevention: HPV vaccines. , 2012, , 107-143.		0
77	Reducing HPV-Associated Cancer Globally. <i>Cancer Prevention Research</i> , 2012, 5, 18-23.	0.7	184
79	Introduction and epidemiological data. , 2012, , 1-14.		0

#	ARTICLE	IF	CITATIONS
80	Current topics in infectious diseases of the skin. Expert Review of Dermatology, 2012, 7, 93-106.	0.3	2
81	Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. Yearbook of Pediatrics, 2012, 2012, 277-279.	0.2	0
82	Quadrivalent human papillomavirus vaccine: Updated recommendations for males. Journal of the American Pharmacists Association: JAPhA, 2012, 52, 289-290.	0.7	1
83	Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Review of Vaccines, 2012, 11, 645-657.	2.0	24
84	Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges. Clinical Microbiology and Infection, 2012, 18, 64-69.	2.8	17
85	Success of HPV vaccination is now a matter of coverage. Lancet Oncology, The, 2012, 13, 10-12.	5.1	35
86	Adult immunizations: updates and practical guidance for the practicing allergist-immunologist. Annals of Allergy, Asthma and Immunology, 2012, 109, 295-302.	0.5	0
89	Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infectious Diseases, The, 2012, 12, 627-634.	4.6	50
90	Epithelial Cell Responses to Infection with Human Papillomavirus. Clinical Microbiology Reviews, 2012, 25, 215-222.	5.7	329
91	Let's Talk About HPV: Examining College Male Perceptions of the HPV Vaccine. Qualitative Research Reports in Communication, 2012, 13, 28-36.	1.1	14
92	Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine, 2012, 30, 4284-4291.	1.7	36
93	Interest in having HPV vaccination among adolescent boys in England. Vaccine, 2012, 30, 4505-4510.	1.7	29
94	Human papillomavirus vaccine knowledge and hypothetical acceptance among women in Appalachia Ohio. Vaccine, 2012, 30, 5349-5357.	1.7	9
95	Acceptability of human papillomavirus vaccination and sexual experience prior to disclosure to health care providers among men who have sex with men in Vancouver, Canada: Implications for targeted vaccination programs. Vaccine, 2012, 30, 5755-5760.	1.7	36
96	Vaccination to protect against infection of the female reproductive tract. Expert Review of Clinical Immunology, 2012, 8, 81-94.	1.3	14
97	A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. Expert Review of Vaccines, 2012, 11, 395-406.	2.0	11
98	Evidence-Based Treatment and Prevention of External Genital Warts in Female Pediatric and Adolescent Patients. Journal of Pediatric and Adolescent Gynecology, 2012, 25, 150-154.	0.3	14
99	The prevalence of anal human papillomavirus among young HIV negative men who have sex with men. BMC Infectious Diseases, 2012, 12, 341.	1.3	11

#	ARTICLE	IF	CITATIONS
100	Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark. BMC Public Health, 2012, 12, 1082.	1.2	27
101	Designing Messages to Motivate Parents To Get Their Preteenage Sons Vaccinated Against Human Papillomavirus. Perspectives on Sexual and Reproductive Health, 2012, 44, 39-47.	0.9	36
102	Cervical Cancer Screening in the Era of Human Papillomavirus Testing and Vaccination. Journal of Midwifery and Women's Health, 2012, 57, 569-576.	0.7	6
103	Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nature Reviews Microbiology, 2012, 10, 681-692.	13.6	199
104	Emerging human papillomavirus vaccines. Expert Opinion on Emerging Drugs, 2012, 17, 469-492.	1.0	62
105	Biology of Human Papillomavirus Infection and Immune Therapy for HPV-Related Head and Neck Cancers. Otolaryngologic Clinics of North America, 2012, 45, 807-822.	0.5	48
106	Prevention of HPV-Associated Diseases in the United States. , 2012, , 211-255.		0
107	Warts and all: Human papillomavirus in primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2012, 130, 1030-1048.	1.5	150
108	A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine, 2012, 30, F123-F138.	1.7	610
109	HPV Vaccination and Cervical Cancer. Current Oncology Reports, 2012, 14, 559-567.	1.8	10
110	Introducing human papillomavirus vaccines into the health system in South Africa. Vaccine, 2012, 30, C28-C34.	1.7	17
111	Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. Vaccine, 2012, 30, F157-F167.	1.7	97
112	Human Papillomavirus Vaccines: Where Do They Fit in HIV-Infected Individuals?. Current HIV/AIDS Reports, 2012, 9, 278-286.	1.1	14
113	Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males. Drugs in R and D, 2012, 12, 235-238.	1.1	2
115	Reframing Cervical Cancer Prevention. Expanding the Field Towards Prevention of Human Papillomavirus Infections and Related Diseases. Vaccine, 2012, 30, F1-F11.	1.7	40
116	Development of Novel Vaccines. , 2012, , .		2
117	Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Economics Review, 2012, 2, 19.	0.8	20
118	Simultaneous Detection and Differentiation of Human Papillomavirus Genotypes 6, 11, 16 and 18 by AllGlo Quadruplex Quantitative PCR. PLoS ONE, 2012, 7, e48972.	1.1	14

#	ARTICLE	IF	CITATIONS
120	Major clinical research advances in gynecologic cancer in 2011. <i>Journal of Gynecologic Oncology</i> , 2012, 23, 53.	1.0	34
122	Synthesizing Vaccines with Microbes. , 2012, , 125-144.		2
123	Immunogenicity, Efficacy, Effectiveness and Overall Impact of HPV Vaccines. , 2012, , 257-272.		1
124	Tumor-specific and gender-specific pre-vaccination distribution of human papillomavirus types 6 and 11 in anogenital warts and laryngeal papillomas: A study on 574 tissue specimens. <i>Journal of Medical Virology</i> , 2012, 84, 1233-1241.	2.5	57
125	EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. <i>International Journal of Cancer</i> , 2012, 131, 1969-1982.	2.3	204
126	Epidemiology and Clinical Aspects of HPV in Head and Neck Cancers. <i>Head and Neck Pathology</i> , 2012, 6, 16-24.	1.3	219
127	Update on Human Papillomavirus Vaccines: Life Saver or Controversy Magnet?. <i>Clinical Microbiology Newsletter</i> , 2012, 34, 85-91.	0.4	1
129	What's New in Sexually Transmitted Infection Management: Changes in the 2010 Guidelines from the Centers for Disease Control and Prevention. <i>Journal of Midwifery and Women's Health</i> , 2012, 57, 276-284.	0.7	7
130	Cancers with increasing incidence trends in the United States: 1999 through 2008. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 118-128.	157.7	606
131	Parents, adolescents, children and the human papillomavirus vaccine: a review. <i>International Nursing Review</i> , 2012, 59, 305-311.	1.5	33
132	Increased incidence of penile cancer and high-grade penile intraepithelial neoplasia in Denmark 1978-2008: a nationwide population-based study. <i>Cancer Causes and Control</i> , 2012, 23, 273-280.	0.8	66
133	Cervical Cancer Knowledge and Prevention Among College Women. <i>Journal of Community Health</i> , 2013, 38, 997-1002.	1.9	10
134	Male Genital Lesions. , 2013, , .		1
135	Human Papillomavirus in Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 189-200.	2.6	24
136	Systematic review of the incidence and prevalence of genital warts. <i>BMC Infectious Diseases</i> , 2013, 13, 39.	1.3	290
137	Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. <i>BMC Cancer</i> , 2013, 13, 10.	1.1	60
138	Rome consensus conference - statement; human papilloma virus diseases in males. <i>BMC Public Health</i> , 2013, 13, 117.	1.2	20
139	Human papillomavirus vaccines. , 2013, , 235-256.		5



#	ARTICLE	IF	CITATIONS
141	Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection. <i>Vaccine</i> , 2013, 31, 1931-1936.	1.7	8
142	Hospitalization for diseases attributable to human papillomavirus in the Veneto Region (North-East) Tj ETQq1 1 0.784314 rgBT /Overl	1.3	9
143	Towards the eradication of HPV infection through universal specific vaccination. <i>BMC Public Health</i> , 2013, 13, 642.	1.2	41
144	Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. <i>Vaccine</i> , 2013, 31, 3849-3855.	1.7	42
145	Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United Statesâ€”Do we need a broader vaccine policy?. <i>Vaccine</i> , 2013, 31, 5500-5505.	1.7	43
146	Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. <i>Vaccine</i> , 2013, 31, 3899-3905.	1.7	10
147	Staging and Risk Stratification in Penile Cancer. , 2013, , 11-42.		0
148	The Epidemiology and Control of Human Papillomavirus Infection and Clinical Disease. , 2013, , 315-352.		1
149	Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil. <i>Journal of Clinical Virology</i> , 2013, 57, 147-151.	1.6	8
151	Healthy Cities. , 2013, , 931-932.		0
152	Infecci3n por el virus del papiloma humano en el hombre y su relaci3n con el c3ncer: estado actual y prospectivas. <i>Revista Internacional De Androlog3a</i> , 2013, 11, 25-30.	0.1	3
153	Safety of Human Papillomavirus Vaccines: A Review. <i>Drug Safety</i> , 2013, 36, 393-412.	1.4	100
154	Clinical trials of human papillomavirus vaccines and beyond. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 400-410.	12.5	147
155	Human Papillomavirus Vaccination. <i>Obstetrics and Gynecology Clinics of North America</i> , 2013, 40, 177-197.	0.7	18
156	Penile Carcinoma: Lessons Learned from Vulvar Carcinoma. <i>Journal of Urology</i> , 2013, 189, 17-24.	0.2	32
157	Influence of Oral Sex and Oral Cancer Information on Young Adults' Oral Sexual-Risk Cognitions and Likelihood of HPV Vaccination. <i>Journal of Sex Research</i> , 2013, 50, 95-102.	1.6	28
158	HPV Vaccination of Boys in Primary Care Practices. <i>Academic Pediatrics</i> , 2013, 13, 466-474.	1.0	38
160	Changes in Incidence of Anogenital Warts Diagnoses After the Introduction of Human Papillomavirus Vaccination in Germanyâ€”An Ecologic Study. <i>Sexually Transmitted Diseases</i> , 2013, 40, 28-31.	0.8	35

#	ARTICLE	IF	CITATIONS
161	Meningococcal vaccines. , 2013, , 388-418.		12
162	Current update on the treatment of genital warts. Expert Review of Dermatology, 2013, 8, 321-332.	0.3	4
163	High-risk human papillomavirus prevalence is associated with HIV infection among heterosexual men in Rakai, Uganda. Sexually Transmitted Infections, 2013, 89, 122-127.	0.8	14
164	HPV vaccination to prevent anal cancer in men who have sex with men. Sexually Transmitted Infections, 2013, 89, 342-343.	0.8	24
166	Near Elimination of Genital Warts in Australia Predicted With Extension of Human Papillomavirus Vaccination to Males. Sexually Transmitted Diseases, 2013, 40, 833-835.	0.8	41
167	Human Papilloma Virus Prevalence in a Multiethnic Screening Population. Otolaryngology - Head and Neck Surgery, 2013, 148, 436-442.	1.1	14
168	Development and Impact of Human Papillomavirus Vaccines. Clinical Obstetrics and Gynecology, 2013, 56, 10-16.	0.6	11
169	Laboratory Management of Cervical Intraepithelial Neoplasia. Advances in Anatomic Pathology, 2013, 20, 86-94.	2.4	12
170	Primary prevention and vaccination for penile cancer. Therapeutic Advances in Urology, 2013, 5, 161-169.	0.9	21
171	HPV vaccine acceptability among men: a systematic review and meta-analysis. Sexually Transmitted Infections, 2013, 89, 568-574.	0.8	137
172	HPV and HIV coinfection: a complex interaction resulting in epidemiological, clinical and therapeutic implications. Future Virology, 2013, 8, 903-915.	0.9	21
173	Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany. Journal of Medical Economics, 2013, 16, 364-371.	1.0	7
175	Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Pediatric Infectious Disease Journal, 2013, 32, i.	1.1	46
176	The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection. Therapeutic Advances in Vaccines, 2013, 1, 81-92.	2.7	15
177	Vaccinate boys with the <sc>HPV</sc> vaccine? Really?. Journal for Specialists in Pediatric Nursing, 2013, 18, 165-169.	0.6	3
178	Immunogenicity of Quadrivalent Human Papillomavirus Vaccine in Organ Transplant Recipients. American Journal of Transplantation, 2013, 13, 2411-2417.	2.6	108
179	Annual Report to the Nation on the Status of Cancer, 1975â€“2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)â€“Associated Cancers and HPV Vaccination Coverage Levels. Journal of the National Cancer Institute, 2013, 105, 175-201.	3.0	886
180	Significant Decrease in the Incidence of Genital Warts in Young Danish Women After Implementation of a National Human Papillomavirus Vaccination Program. Sexually Transmitted Diseases, 2013, 40, 130-135.	0.8	130

#	ARTICLE	IF	CITATIONS
181	Incidence of Genital Warts in Adolescents and Young Adults in an Integrated Health Care Delivery System in the United States Before Human Papillomavirus Vaccine Recommendations. Sexually Transmitted Diseases, 2013, 40, 534-538.	0.8	18
182	HPV vaccines for circumpolar health: summary of plenary session, "Opportunities for Prevention: Global HPV Vaccine" and "Human Papillomavirus Prevention: The Nordic Experience", International Journal of Circumpolar Health, 2013, 72, 21070.	0.5	2
183	Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany. ClinicoEconomics and Outcomes Research, 2013, 5, 203.	0.7	12
184	Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Canadian Urological Association Journal, 2013, 7, 797.	0.3	12
185	Human Papilloma Virus Infection in Head and Neck Cancer. Deutsches A&#x0308;rztblatt International, 2013, 110, 184-90, 190e1.	0.6	30
186	Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?. PLoS ONE, 2013, 8, e67072.	1.1	5
187	Attitudes Surrounding Implementation of the HPV Vaccine for Males among Primary Care Providers Serving Large Minority Populations. Journal of Health Care for the Poor and Underserved, 2013, 24, 768-776.	0.4	7
188	Prevention of Anal Condyloma with Quadrivalent Human Papillomavirus Vaccination of Older Men Who Have Sex with Men. PLoS ONE, 2014, 9, e93393.	1.1	46
189	Fusion of CTLA-4 with HPV16 E7 and E6 Enhanced the Potency of Therapeutic HPV DNA Vaccine. PLoS ONE, 2014, 9, e108892.	1.1	19
190	The Road Ahead for Cervical Cancer Prevention and Control. Current Oncology, 2014, 21, 255-264.	0.9	41
191	Sexually transmitted infections of the anus and rectum. World Journal of Gastroenterology, 2014, 20, 15262.	1.4	69
192	Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives. Sexual Health, 2014, 11, 511.	0.4	25
193	Genital warts. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 1063-1073.	1.4	47
194	Alternative dosage schedules with HPV virus-like particle vaccines. Expert Review of Vaccines, 2014, 13, 1027-1038.	2.0	41
195	Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention. Human Vaccines and Immunotherapeutics, 2014, 10, 1974-1984.	1.4	10
196	Human papillomavirus vaccination. British Journal of Hospital Medicine (London, England: 2005), 2014, 75, C165-C168.	0.2	0
197	Periodontal Disease, Atherosclerosis, Adverse Pregnancy Outcomes, and Head-and-Neck Cancer. Advances in Dental Research, 2014, 26, 47-55.	3.6	70
198	HPV vaccination in boys and men. Human Vaccines and Immunotherapeutics, 2014, 10, 2109-2111.	1.4	89

#	ARTICLE	IF	CITATIONS
199	Comparison of the immunogenicity of Cervarix <sup>®</sup> and Gardasil <sup>®</sup> human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1147-1154.	1.4	45
200	Vaccination against Human Papilloma Virus infection in male adolescents: Knowledge, attitudes, and acceptability among parents in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2536-2542.	1.4	60
201	Factors impacting HPV vaccination: lessons for health care professionals. <i>Expert Review of Vaccines</i> , 2014, 13, 1013-1026.	2.0	35
202	Human Papillomavirus (HPV) Risk Factors, Vaccination Patterns, and Vaccine Perceptions Among a Sample of Male College Students. <i>Journal of American College Health</i> , 2014, 62, 186-192.	0.8	52
203	The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants. <i>International Journal of STD and AIDS</i> , 2014, 25, 332-340.	0.5	5
204	Genitoanal Human Papillomavirus Infection and Associated Neoplasias. <i>Current Problems in Dermatology</i> , 2014, 45, 98-122.	0.8	10
205	HPV vaccination in boys and men. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2106-2108.	1.4	16
206	The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. <i>Expert Review of Vaccines</i> , 2014, 13, 1279-1290.	2.0	71
208	Impact of the Quadrivalent HPV Vaccine on Disease Recurrence in Men Exposed to HPV Infection: A Randomized Study. <i>Journal of Sexual Medicine</i> , 2014, 11, 2785-2791.	0.3	28
209	Human Papillomavirus Genotype Prevalence in Invasive Penile Cancers from a Registry-Based United States Population. <i>Frontiers in Oncology</i> , 2014, 4, 9.	1.3	48
210	Invited Commentary: Multiple Human Papillomavirus Infections and Type Replacement—Anticipating the Future After Human Papillomavirus Vaccination. <i>American Journal of Epidemiology</i> , 2014, 180, 1076-1081.	1.6	11
211	Vaccinate boys as well as girls against HPV: it works, and it may be cost effective. <i>BMJ</i> , The, 2014, 349, g4834-g4834.	3.0	10
212	Characteristics of Memory B Cells Elicited by a Highly Efficacious HPV Vaccine in Subjects with No Pre-existing Immunity. <i>PLoS Pathogens</i> , 2014, 10, e1004461.	2.1	54
213	Committee Opinion No. 588. <i>Obstetrics and Gynecology</i> , 2014, 123, 712-718.	1.2	17
214	Adolescent sexual activity and cancer risk: physicians' duty to inform?. <i>Current Medical Research and Opinion</i> , 2014, 30, 1827-1831.	0.9	8
216	Effect of the decision-making process in the family on HPV vaccination rates among adolescents 9–17 years of age. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1807-1811.	1.4	42
217	Global evidence reaffirms the case for routine HPV and potential HIV adolescent vaccination in South Africa. <i>Future Virology</i> , 2014, 9, 207-220.	0.9	2
218	Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 763-765.	0.7	11

#	ARTICLE	IF	CITATIONS
220	Vaccination against HPV-Associated Neoplasias. <i>Geburtshilfe Und Frauenheilkunde</i> , 2014, 74, 233-241.	0.8	2
221	Prevalence of human papillomavirus in men who have sex with men in the era of an effective vaccine; a call to act. <i>HIV Medicine</i> , 2014, 15, 499-504.	1.0	21
222	Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 269-281.	0.7	31
223	Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers. <i>International Journal of Cancer</i> , 2014, 135, 996-1001.	2.3	42
224	HPV in genital cancers (at the exception of cervical cancer) and anal cancers. <i>Presse Medicale</i> , 2014, 43, e423-e428.	0.8	48
225	HPV Seroconversion Following Anal and Penile HPV Infection in HIV-Negative and HIV-Infected MSM. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2455-2461.	1.1	13
226	Vacunas frente al virus del papiloma humano. <i>Vacunas</i> , 2014, 15, 125-145.	1.1	1
228	Anal Condyloma Treatment and Recurrence in HIV-negative Men Who Have Sex With Men. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 752-761.	0.7	19
229	Prevalence of Genital Warts Among Sexually Transmitted Disease Clinic Patients—Sexually Transmitted Disease Surveillance Network, United States, January 2010 to December 2011. <i>Sexually Transmitted Diseases</i> , 2014, 41, 89-93.	0.8	19
230	Evaluation of a Surveillance Case Definition for Anogenital Warts, Kaiser Permanente Northwest. <i>Sexually Transmitted Diseases</i> , 2014, 41, 496-500.	0.8	1
231	Incidence of and risk factors for type-specific anal human papillomavirus infection among HIV-positive MSM. <i>Aids</i> , 2014, 28, 1341-1349.	1.0	55
232	Would Young Women Attending Sexually Transmitted Disease Clinics Benefit From Human Papillomavirus Vaccination? An Assessment of Human Papillomavirus DNA and Seropositivity From Human Papillomavirus Sentinel Surveillance, 2003–2005. <i>Sexually Transmitted Diseases</i> , 2014, 41, 46-49.	0.8	2
233	Long-term efficacy and safety of human papillomavirus vaccination. <i>International Journal of Women's Health</i> , 2014, 6, 999.	1.1	80
234	Chemoprevention of Squamous Cell Carcinoma of the Head and Neck: No Time to Lose Momentum. <i>Cancer Prevention Research</i> , 2014, 7, 279-282.	0.7	5
235	Physicians' Human Papillomavirus Vaccine Recommendations in the Context of Permissive Guidelines for Male Patients: A National Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2126-2135.	1.1	30
236	Human papillomavirus awareness among HIV-infected drug users in two urban areas. <i>International Journal of STD and AIDS</i> , 2014, 25, 992-996.	0.5	1
237	Cancer Immunoprevention—The Next Frontier. <i>Cancer Prevention Research</i> , 2014, 7, 1072-1080.	0.7	21
238	Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. <i>European Journal of Cancer Prevention</i> , 2014, 23, 206-224.	0.6	88

#	ARTICLE	IF	CITATIONS
239	Immunizations following solid-organ transplantation. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 329-335.	1.3	21
240	Prophylactic vaccines for patients with human papillomavirus diseases (HPV). <i>Journal of Coloproctology</i> , 2014, 34, 001-003.	0.1	0
242	Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. <i>Infectious Agents and Cancer</i> , 2014, 9, 4.	1.2	14
243	Implications for human papillomavirus in penile cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 53.e1-53.e8.	0.8	53
245	Prospects for prevention of HPV-driven oropharynx cancer. <i>Oral Oncology</i> , 2014, 50, 555-559.	0.8	46
246	Immunity and squamous cell carcinoma of the anus: Epidemiological, clinical and therapeutic aspects. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 18-23.	0.7	8
247	Viruses and Human Cancer. <i>Recent Results in Cancer Research</i> , 2014, , .	1.8	1
248	Cancers of the anal canal: diagnosis, treatment and future strategies. <i>Future Oncology</i> , 2014, 10, 1427-1441.	1.1	7
249	An Integrative Review of Guidelines for Anal Cancer Screening in HIV-Infected Persons. <i>AIDS Patient Care and STDs</i> , 2014, 28, 350-357.	1.1	52
250	Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia. <i>Vaccine</i> , 2014, 32, 6941-6947.	1.7	42
251	Challenges and controversies in the management of penile cancer. <i>Nature Reviews Urology</i> , 2014, 11, 702-711.	1.9	19
252	Human papillomavirus vaccine acceptance among young men in Bangalore, India. <i>International Journal of Dermatology</i> , 2014, 53, e486-91.	0.5	16
253	Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 527-534.	1.4	5
254	Long-term Study of a Quadrivalent Human Papillomavirus Vaccine. <i>Pediatrics</i> , 2014, 134, e657-e665.	1.0	93
255	Cancers in People with HIV and AIDS. , 2014, , .		2
256	No evidence for a protective effect of naturally induced HPV antibodies on subsequent anogenital HPV infection in HIV-negative and HIV-infected MSM. <i>Journal of Infection</i> , 2014, 69, 375-386.	1.7	18
257	Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts. <i>Drugs</i> , 2014, 74, 1253-1283.	4.9	56
258	Anal Pap smears and anal cancer: What dermatologists should know. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 985-992.	0.6	21

#	ARTICLE	IF	CITATIONS
259	Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. <i>Vaccine</i> , 2014, 32, 5880-5887.	1.7	38
260	The potential impact of HPV-16 reactivation on prevalence in older Australians. <i>BMC Infectious Diseases</i> , 2014, 14, 312.	1.3	9
261	Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males. <i>Vaccine</i> , 2014, 32, 693-699.	1.7	17
262	Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women. <i>Clinical Infectious Diseases</i> , 2014, 59, 127-135.	2.9	127
263	Incidence, Clearance, and Disease Progression of Genital Human Papillomavirus Infection in Heterosexual Men. <i>Journal of Infectious Diseases</i> , 2014, 210, 192-199.	1.9	42
264	Early Acquisition of Anogenital Human Papillomavirus Among Teenage Men Who Have Sex With Men. <i>Journal of Infectious Diseases</i> , 2014, 209, 642-651.	1.9	57
265	Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1997-2008.	1.1	137
267	Actualizaci3n en el virus del papiloma humano. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2014, 21, 67-75.	0.0	1
269	Acceptability of the human papillomavirus vaccine and reasons for non-vaccination among parents of adolescent sons. <i>Vaccine</i> , 2014, 32, 3883-3885.	1.7	64
270	How very young men who have sex with men view vaccination against human papillomavirus. <i>Vaccine</i> , 2014, 32, 3936-3941.	1.7	28
271	What parents and their adolescent sons suggest for male HPV vaccine messaging.. <i>Health Psychology</i> , 2014, 33, 448-456.	1.3	25
272	Bundling Human Papillomavirus Vaccination and Rapid Human Immunodeficiency Virus Testing for Young Gay and Bisexual Men. <i>LGBT Health</i> , 2014, 1, 233-237.	1.8	10
273	Human papillomavirus vaccination for men: advancing policy and practice. <i>Future Virology</i> , 2014, 9, 1033-1047.	0.9	7
274	An Overview of Quadrivalent Human Papillomavirus Vaccine Safety. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 983-991.	1.1	103
275	Human papillomavirus vaccine initiation among 9-13-year-olds in the United States. <i>Preventive Medicine Reports</i> , 2015, 2, 892-898.	0.8	40
276	How can we achieve HPV control in Europe?. <i>Future Virology</i> , 2015, 10, 1125-1127.	0.9	1
277	Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 384-400.	157.7	361
278	A different entity: a population based study of characteristics and recurrence patterns in oropharyngeal squamous cell carcinomas. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2015, 44, 30.	0.9	2

#	ARTICLE	IF	CITATIONS
279	Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status. <i>BMC Infectious Diseases</i> , 2015, 15, 459.	1.3	42
280	Current status of human papillomavirus vaccination. <i>Current Opinion in Oncology</i> , 2015, 27, 399-404.	1.1	28
281	Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 326-332.	0.9	9
282	An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11-15 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 627-634.	1.1	31
283	Carcinomi associati al papillomavirus umano: conoscenze, ruolo e attitudini dei medici otorinolaringoiatri in tema di prevenzione. <i>Acta Otorhinolaryngologica Italica</i> , 2015, 35, 379-385.	0.7	9
284	Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. <i>Journal of Clinical Medicine</i> , 2015, 4, 1126-1155.	1.0	33
285	Revised Adult Immunization Guideline Recommended by the Korean Society of Infectious Diseases, 2014. <i>Infection and Chemotherapy</i> , 2015, 47, 68.	1.0	30
286	Historical review of clinical vaccine studies at Oswaldo Cruz Institute and Oswaldo Cruz Foundation - technological development issues. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2015, 110, 114-124.	0.8	0
287	Current and Next-generation Vaccines against Human Papillomaviruses. <i>Journal of Bacteriology and Virology</i> , 2015, 45, 189.	0.0	0
288	Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. <i>Journal of Clinical Medicine</i> , 2015, 4, 614-633.	1.0	78
289	Human papillomavirus knowledge and intent to vaccinate among young college age males. <i>Journal of Epidemiological Research</i> , 2015, 2, .	0.6	3
290	Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. <i>BMJ, The</i> , 2015, 350, h2016-h2016.	3.0	75
292	From the monovalent to the nine-valent HPV vaccine. <i>Clinical Microbiology and Infection</i> , 2015, 21, 827-833.	2.8	57
293	Novel Approaches for Vaccination Against HPV-Induced Cancers. <i>Current Topics in Microbiology and Immunology</i> , 2015, 405, 33-53.	0.7	1
294	A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 992-998.	1.1	89
295	Acceptability of human papillomavirus vaccination among academics at the University of KwaZulu-Natal, South Africa. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2015, 57, 318-321.	0.2	10
296	Molecular cancer prevention: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 345-383.	157.7	83
297	Skin and Mucosal Human Papillomavirus Seroprevalence in Persons with Fanconi Anemia. <i>Vaccine Journal</i> , 2015, 22, 413-420.	3.2	12



#	ARTICLE	IF	CITATIONS
298	Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions. <i>BMJ Open</i> , 2015, 5, e008439.	0.8	19
299	Geospatial patterns of human papillomavirus vaccine uptake in Minnesota. <i>BMJ Open</i> , 2015, 5, e008617.	0.8	14
300	A 9-Valent HPV Vaccine in Women. <i>New England Journal of Medicine</i> , 2015, 372, 2566-2569.	13.9	13
301	Seroconversion following anal and genital HPV infection in men: The HIM study. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2015, 1, 109-115.	4.5	47
302	Approach and Management of Cervical Cancer. , 2015, , 435-486.		0
303	Human papillomavirus vaccination uptake and completion as a preventive health measure among female adolescents. <i>Nursing Outlook</i> , 2015, 63, 341-348.	1.5	6
304	Premalignant neoplasms of the anus and perianal skin. <i>Seminars in Colon and Rectal Surgery</i> , 2015, 26, 96-102.	0.2	0
305	Human Papillomavirus Virus (HPV) Genotype- and Age-Specific Analyses of External Genital Lesions Among Men in the HPV Infection in Men (HIM) Study. <i>Journal of Infectious Diseases</i> , 2015, 211, 1060-1067.	1.9	59
306	Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies. <i>Epidemics</i> , 2015, 11, 32-47.	1.5	14
307	Current trends in the etiology and diagnosis of HPV-related head and neck cancers. <i>Cancer Medicine</i> , 2015, 4, 596-607.	1.3	98
309	A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. <i>New England Journal of Medicine</i> , 2015, 372, 711-723.	13.9	1,090
310	International Gynecologic Cancer Society (IGCS) 2014: Meeting report. <i>Gynecologic Oncology</i> , 2015, 136, 185-188.	0.6	0
311	Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 1-8.	0.3	2
312	University Students' Knowledge and Attitudes Regarding Cervical Cancer, Human Papillomavirus, and Human Papillomavirus Vaccines in Turkey. <i>Journal of American College Health</i> , 2015, 63, 13-22.	0.8	17
313	An update on anal neoplasia. <i>Histopathology</i> , 2015, 66, 147-160.	1.6	61
314	Evaluation of human papillomavirus DNA detection in samples obtained for routine Chlamydia trachomatis screening. <i>Journal of Clinical Virology</i> , 2015, 64, 88-91.	1.6	6
315	Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2015, 10, 219-246.	1.0	11
316	Recent progress in vaccination against human papillomavirus-mediated cervical cancer. <i>Reviews in Medical Virology</i> , 2015, 25, 54-71.	3.9	32

#	ARTICLE	IF	CITATIONS
317	Human papilloma virus vaccination: impact and recommendations across the world. <i>Therapeutic Advances in Vaccines</i> , 2015, 3, 3-12.	2.7	52
318	How to best measure the effectiveness of male human papillomavirus vaccine programmes?. <i>Clinical Microbiology and Infection</i> , 2015, 21, 834-841.	2.8	15
319	A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. <i>Cancer</i> , 2015, 121, 1785-1792.	2.0	51
321	Immunogenicity and safety of the 9-valent HPV vaccine in men. <i>Vaccine</i> , 2015, 33, 6892-6901.	1.7	104
322	Systematic review of primary prevention human papillomavirus interventions targeting college students. <i>International Journal of Sexual Health</i> , 2015, 27, 125-144.	1.2	13
323	Present status of human papillomavirus vaccine development and implementation. <i>Lancet Oncology</i> , 2015, 16, e206-e216.	5.1	165
326	Immune Escape and Immunotherapy of HPV-Related Oropharyngeal Cancer: Has the Future Arrived?. <i>Current Otorhinolaryngology Reports</i> , 2015, 3, 63-72.	0.2	0
327	Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. <i>British Journal of Cancer</i> , 2015, 112, 1585-1593.	2.9	50
328	US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv086.	3.0	550
330	Human Papillomavirus (HPV) Infections and the Importance of HPV Vaccination. <i>Current Epidemiology Reports</i> , 2015, 2, 101-109.	1.1	20
331	Anal cancer: Current standards in care and recent changes in practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 139-162.	157.7	81
332	9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. <i>Expert Review of Vaccines</i> , 2015, 14, 1405-1419.	2.0	38
333	Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)-The MAM Study. <i>Vaccine</i> , 2015, 33, 5640-5646.	1.7	51
334	Parental attitudes towards male human papillomavirus vaccination: a pan-European cross-sectional survey. <i>BMC Public Health</i> , 2015, 15, 624.	1.2	58
335	An anal cancer screening program for MSM in Italy: Prevalence of multiple HPV types and vaccine-targeted infections. <i>Journal of Clinical Virology</i> , 2015, 72, 49-54.	1.6	14
336	Human papillomavirus vaccine trials and tribulations. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 743-756.	0.6	25
337	An analysis of HPV infection incidence and clearance by genotype and age in men: The HPV Infection in Men (HIM) Study. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2015, 1, 126-135.	4.5	23
338	HPV Vaccination: Current Global Status. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 220-233.	0.3	20

#	ARTICLE	IF	CITATIONS
339	The Beginning of the End: Vaccine Prevention of HPV-Driven Cancers. Journal of the National Cancer Institute, 2015, 107, djv128-djv128.	3.0	7
340	Sexually Transmitted Infections. Urologic Clinics of North America, 2015, 42, 507-518.	0.8	29
341	A urologist's contemporary guide to penile cancer. Scandinavian Journal of Urology, 2015, 49, 427-432.	0.6	2
342	The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination. Vaccine, 2015, 33, 5357-5364.	1.7	7
343	Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa. Human Vaccines and Immunotherapeutics, 2015, 11, 1323-1330.	1.4	18
344	European Code against Cancer 4th Edition: Infections and Cancer. Cancer Epidemiology, 2015, 39, S120-S138.	0.8	34
345	Acceptability of human papillomavirus vaccine among parents of junior middle school students in Jinan, China. Vaccine, 2015, 33, 2570-2576.	1.7	33
346	Providers' beliefs about the effectiveness of the HPV vaccine in preventing cancer and their recommended age groups for vaccination: Findings from a provider survey, 2012. Preventive Medicine, 2015, 81, 405-411.	1.6	30
347	Sociodemographic Differences in Human Papillomavirus Vaccine Initiation by Adolescent Males. Journal of Adolescent Health, 2015, 57, 506-514.	1.2	9
348	HPV prophylactic vaccines: lessons learned from 10 years experience. Future Virology, 2015, 10, 999-1009.	0.9	7
349	Prevalence, Incidence, and Clearance of Anogenital Warts in Kenyan Men Reporting High-Risk Sexual Behavior, Including Men Who Have Sex With Men. Open Forum Infectious Diseases, 2015, 2, ofv070.	0.4	13
350	A high and increasing HPV prevalence in tonsillar cancers in Eastern Denmark, 2000-2010: The largest registry-based study to date. International Journal of Cancer, 2015, 136, 2196-2203.	2.3	103
351	Site-specific human papillomavirus infection in adolescent men who have sex with men (HYPER): an observational cohort study. Lancet Infectious Diseases, The, 2015, 15, 65-73.	4.6	40
352	Indications for the HPV vaccine in adolescents: A review of the literature. Journal of Infection and Public Health, 2015, 8, 105-116.	1.9	8
353	Awareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs. World Journal of Urology, 2015, 33, 873-880.	1.2	16
354	Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. Expert Review of Vaccines, 2015, 14, 119-133.	2.0	11
355	Factors influencing the recommendation of the Human Papillomavirus vaccine by South African doctors working in a tertiary hospital. African Health Sciences, 2016, 16, 567.	0.3	11
356	Ten years of anti-HPV vaccinations: what do we know?. Przegląd Menopauzalny, 2016, 3, 170-175.	0.6	7

#	ARTICLE	IF	CITATIONS
357	Human Papillomavirus Vaccines. , 2016, , 245-263.		14
358	HPV Infection and Prevention of HPV Infection in Men Who Have Sex with Men (MSM). , 0, , .		1
359	Why not boys? The human papillomavirus vaccine schedule in the UK. British Journal of School Nursing, 2016, 11, 438-442.	0.1	0
360	Response to letter: limitations of human papillomavirus <scp>DNA</scp> testing in measuring previous exposure and vaccine protection. HIV Medicine, 2016, 17, 557-558.	1.0	0
361	Adolescent Male Human Papillomavirus Vaccination. Global Pediatric Health, 2016, 3, 2333794X1664237.	0.3	7
362	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. International Journal of Cancer, 2016, 139, 510-517.	2.3	19
363	Significant Reduction in the Incidence of Genital Warts in Young Men 5 Years Into the Danish Human Papillomavirus Vaccination Program for Girls and Women. Sexually Transmitted Diseases, 2016, 43, 238-242.	0.8	41
364	The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. Laryngoscope, 2016, 126, 894-900.	1.1	111
365	The incidence, clearance and persistence of non-cervical human papillomavirus infections: a systematic review of the literature. BMC Infectious Diseases, 2016, 16, 293.	1.3	76
366	Premalignant penile lesions. Journal of Clinical Urology, 2016, 9, 216-222.	0.1	1
367	Antibody responses following incident anal and penile infection with human papillomavirus in teenage men who have sex with men. International Journal of Cancer, 2016, 139, 639-646.	2.3	7
368	Using the Health Belief Model to Examine the Link between HPV Knowledge and Self-Efficacy for Preventive Behaviors of Male Students at a Two-Year College in New York City. Behavioral Medicine, 2016, 42, 205-210.	1.0	27
369	The male Screen<scp>ING</scp> Study: prevalence of <scp>HPV</scp>-related genital and anal lesions in an urban cohort of <scp>HIV</scp>-positive men in Germany. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 995-1001.	1.3	34
370	HPV vaccines: how many doses are needed for protection?. Future Virology, 2016, 11, 283-292.	0.9	0
371	Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers, 2016, 2, 16086.	18.1	615
372	Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials. Basic and Clinical Andrology, 2016, 26, 16.	0.8	5
373	Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?. Clinical Microbiology and Infection, 2016, 22, S125-S127.	2.8	23
374	Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clinical Infectious Diseases, 2017, 64, ciw845.	2.9	46

#	ARTICLE	IF	CITATIONS
375	HPV vaccination intention among male clients of a large STI outpatient clinic in Amsterdam, the Netherlands. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 178-184.	4.5	10
376	Update on strategies of controlling sexually transmitted infections: Taiwan experience. <i>Urological Science</i> , 2016, 27, 122-130.	0.2	1
377	Infección por virus del papiloma humano: historia natural del cáncer de pene. <i>Gaceta Mexicana De Oncología</i> , 2016, 15, 323-326.	0.0	1
378	Prophylactic HPV vaccination: past, present, and future. <i>Epidemiology and Infection</i> , 2016, 144, 449-468.	1.0	128
379	Human Papillomavirus Vaccination Counseling in Pediatric Training. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 155, 87-93.	1.1	12
380	HPV vaccination: acceptance and influencing factors among young men in Germany. <i>Future Microbiology</i> , 2016, 11, 227-234.	1.0	2
381	T-Cell Epitope Discovery for Therapeutic Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2016, 1403, 779-796.	0.4	11
382	National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5107-5112.	3.3	46
383	Surgical excision alone for stage T1 anal verge cancers in people living with HIV. <i>European Journal of Surgical Oncology</i> , 2016, 42, 813-816.	0.5	19
384	HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1536-1541.	1.4	18
385	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-18.	1.4	49
386	Human papillomavirus L1 protein expressed in <i>Escherichia coli</i> self-assembles into virus-like particles that are highly immunogenic. <i>Virus Research</i> , 2016, 220, 97-103.	1.1	21
387	Missing the Target for Routine Human Papillomavirus Vaccination: Consistent and Strong Physician Recommendations Are Lacking for 11- to 12-Year-Old Males. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1435-1446.	1.1	42
388	Factors associated with early adoption of the HPV vaccine in US male adolescents include Hispanic ethnicity and receipt of other vaccines. <i>Preventive Medicine Reports</i> , 2016, 4, 98-102.	0.8	13
389	Human Papillomavirus Infection and Vaccination in Males. <i>European Urology Focus</i> , 2016, 2, 355-362.	1.6	16
390	Anal Carcinoma. , 2016, , 1019-1034.e4.		0
391	The Role of Human Papilloma Virus in Penile Carcinogenesis and Preneoplastic Lesions. <i>Urologic Clinics of North America</i> , 2016, 43, 419-425.	0.8	43
392	Changing prevalence and treatment outcomes of patients with p16 human papillomavirus related oropharyngeal squamous cell carcinoma in New Zealand. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2016, 54, 898-903.	0.4	10

#	ARTICLE	IF	CITATIONS
393	Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 375-385.	157.7	60
394	Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 481-495.	157.7	55
395	Human Papillomavirus Vaccine Uptake in Adolescent Boys: An Evidence Review. <i>Worldviews on Evidence-Based Nursing</i> , 2016, 13, 390-395.	1.2	9
396	Cancer Prevention: HPV Vaccination. <i>Seminars in Oncology Nursing</i> , 2016, 32, 273-280.	0.7	17
397	New Vaccines on the Horizon. <i>Current Pediatrics Reports</i> , 2016, 4, 74-83.	1.7	0
398	Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study. <i>Cancer Research</i> , 2016, 76, 6066-6075.	0.4	12
399	Public Health Benefits of Routine Human Papillomavirus Vaccination for Adults in the Netherlands: A Mathematical Modeling Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 854-861.	1.9	9
400	Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2016, 214, 1276-1283.	1.9	65
401	A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. <i>Vaccine</i> , 2016, 34, 4205-4212.	1.7	68
402	Prevalence of human papillomavirus in saliva of women with HPV genital lesions. <i>Infectious Agents and Cancer</i> , 2016, 11, 48.	1.2	21
403	Disparities in Provider Recommendation of Human Papillomavirus Vaccination for U.S. Adolescents. <i>Journal of Adolescent Health</i> , 2016, 59, 592-598.	1.2	47
404	Increasing HPV vaccination and eliminating barriers: Recommendations from young men who have sex with men. <i>Vaccine</i> , 2016, 34, 6209-6216.	1.7	44
406	HPV Vaccination: Attitude and Knowledge among German Gynecologists. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 1074-1080.	0.8	1
407	Human Papillomavirus in Kidney Transplant Recipients. <i>Seminars in Nephrology</i> , 2016, 36, 397-404.	0.6	27
408	Change Suboptimal Tactics and Promote a National Mandatory Human Papillomavirus Vaccination Program. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 348-351.	0.9	1
409	Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. <i>BMC Infectious Diseases</i> , 2016, 16, 153.	1.3	38
410	Provider-reported acceptance and use of the Centers for Disease Control and Prevention messages and materials to support HPV vaccine recommendation for adolescent males. <i>Vaccine</i> , 2016, 34, 4229-4234.	1.7	14
411	Interventions to Improve HPV Vaccine Uptake: A Systematic Review. <i>Pediatrics</i> , 2016, 138, .	1.0	174

#	ARTICLE	IF	CITATIONS
412	Impact of HPV vaccination on anogenital warts and respiratory papillomatosis. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1357-1362.	1.4	27
415	Beliefs and knowledge about the human papillomavirus vaccine among undergraduate men. <i>Health Education Journal</i> , 2016, 75, 249-256.	0.6	17
416	Monitoring the impact of HPV vaccine in males—Considerations and challenges. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 106-111.	4.5	20
417	Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men—United States, 2012–2014. <i>Journal of Infectious Diseases</i> , 2016, 214, 689-696.	1.9	48
418	The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 2313-2323.	2.0	72
419	Low- and high-risk human papillomavirus genotype infections in intra-anal warts in HIV-positive men who have sex with men. <i>British Journal of Dermatology</i> , 2016, 175, 735-743.	1.4	27
420	Awareness and acceptance of human papillomavirus (HPV) vaccination among males attending a major sexual health clinic in Wuxi, China: A cross-sectional study. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1551-1559.	1.4	17
421	Human papillomavirus vaccination in HIV-infected women: need for increased coverage. <i>Expert Review of Vaccines</i> , 2016, 15, 105-117.	2.0	26
422	Public health value of universal HPV vaccination. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 157-167.	2.0	46
423	HPV vaccination initiation after the routine-recommended ages of 11–12 in the United States. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 11-16.	4.5	17
424	HPV Vaccination for MSM: Synthesis of the evidence and recommendations from the Quadrivalent Immunization Committee. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1560-1565.	1.4	13
425	High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in São Paulo, Brazil. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2016, 2, 17-20.	4.5	9
426	Human papillomavirus: a strong case for vaccinating boys. <i>Trends in Urology &amp; Men's Health</i> , 2016, 7, 7-11.	0.2	4
427	The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 917-926.	1.1	9
428	Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. <i>Current Opinion in Chemical Biology</i> , 2016, 32, 34-47.	2.8	50
429	Quantitative benefit-risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in males. <i>Expert Review of Vaccines</i> , 2016, 15, 139-148.	2.0	16
430	Oropharyngeal Cancer. , 2016, , 597-628.e6.		1
431	Immunologic approaches to cancer prevention—current status, challenges, and future perspectives. <i>Seminars in Oncology</i> , 2016, 43, 161-172.	0.8	35

#	ARTICLE	IF	CITATIONS
432	Young Hispanic Men and Human Papillomavirus Vaccination Choices. <i>Journal of Transcultural Nursing</i> , 2016, 27, 103-108.	0.6	11
433	Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. <i>Journal of Infectious Diseases</i> , 2016, 213, 199-205.	1.9	56
434	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 119-132.	12.5	154
435	How university students view human papillomavirus (HPV) vaccination: A cross-sectional study in Jinan, China. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 39-46.	1.4	20
436	Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study. <i>European Urology</i> , 2016, 69, 166-173.	0.9	59
437	An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 85-98.	0.7	36
438	Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men. <i>JAMA Oncology</i> , 2017, 3, 810.	3.4	100
439	Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. <i>Dermatology and Therapy</i> , 2017, 7, 5-19.	1.4	286
440	Overview of the benefits and potential issues of the nonavalent <sc>HPV</sc> vaccine. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 136, 258-265.	1.0	18
441	Disease burden of human papillomavirus infection in the Netherlands, 1989â€“2014: the gap between females and males is diminishing. <i>Cancer Causes and Control</i> , 2017, 28, 203-214.	0.8	22
442	Realizing the Potential of Cancer Prevention â€” The Role of Implementation Science. <i>New England Journal of Medicine</i> , 2017, 376, 986-990.	13.9	90
444	AHNS series: Do you know your guidelines? Management of head and neck cancer in the era of human papillomavirus: Educating our patients on human papillomavirus. <i>Head and Neck</i> , 2017, 39, 833-839.	0.9	7
445	Concordance of HPVâ€“DNA in cervical dysplasia or genital warts in women and their monogamous longâ€“term male partners. <i>Journal of Medical Virology</i> , 2017, 89, 1662-1670.	2.5	5
446	Cervical cancer, human papillomavirus and vaccines: assessment of the information retrieved from general knowledge websites in Chile. <i>Public Health</i> , 2017, 148, 19-24.	1.4	7
447	Prevalence and Risk of Penile Human Papillomavirus Infection: Evidence From The National Health and Nutrition Examination Survey 2013â€“2014. <i>Clinical Infectious Diseases</i> , 2017, 64, 1360-1366.	2.9	16
449	Ranpirnase Eradicates Human Papillomavirus in Cultured Cells and Heals Anogenital Warts in a Phase I Study. <i>Antiviral Therapy</i> , 2017, 22, 247-255.	0.6	14
451	HPV-related external genital lesions among men residing in Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2017, 21, 376-385.	0.3	8
452	Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain. <i>Vaccine</i> , 2017, 35, 3342-3346.	1.7	42



#	ARTICLE	IF	CITATIONS
454	The role of HPV vaccination in the prevention of anal dysplasia. <i>Seminars in Colon and Rectal Surgery</i> , 2017, 28, 106-110.	0.2	0
455	A Multiple Streams analysis of the decisions to fund gender-neutral HPV vaccination in Canada. <i>Preventive Medicine</i> , 2017, 100, 123-131.	1.6	15
456	Comparison of the Natural History of Genital HPV Infection among Men by Country: Brazil, Mexico, and the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1043-1052.	1.1	18
457	Mothers, Fathers, Sons, and Human Papillomavirus Immunization Practices. <i>Family and Community Health</i> , 2017, 40, 278-287.	0.5	5
459	Management and Prevention of Infectious Diseases in IBD Patients. , 2017, , 621-638.		0
460	Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1011-1018.	0.6	42
461	Oropharyngeal squamous cell carcinoma and HPV. Systematic review on overall management. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2017, 118, 103-108.	0.5	8
462	Loss of chance associated with sub-optimal HPV vaccination coverage rate in France. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 73-79.	4.5	8
464	Adjuvant Human Papillomavirus Vaccination for Secondary Prevention. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 614.	1.2	41
465	What Is New in the Diagnosis and Management of Penile Cancer?. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 379-384.	0.3	0
466	Should the Surgical Management of Buschke-Lowenstein Tumors Be Aggressive? About 10 Cases. <i>Digestive Surgery</i> , 2017, 34, 247-252.	0.6	4
467	Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 80-84.	4.5	24
468	Using the Theory of Planned Behavior to predict HPV vaccination intentions of college men. <i>Journal of American College Health</i> , 2017, 65, 197-207.	0.8	84
469	Factors associated with parents's attitudes to the HPV vaccination of their adolescent sons : A systematic review. <i>Preventive Medicine</i> , 2017, 95, 26-37.	1.6	109
470	9-Valent human papillomavirus vaccine: a review of the clinical development program. <i>Expert Review of Vaccines</i> , 2017, 16, 1119-1139.	2.0	41
471	Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination. <i>Journal of Infectious Diseases</i> , 2017, 216, 966-968.	1.9	8
473	Burden of HPV-caused cancers in Denmark and the potential effect of HPV-vaccination. <i>Vaccine</i> , 2017, 35, 5939-5945.	1.7	8
474	Tumour virus vaccines: hepatitis B virus and human papillomavirus. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160268.	1.8	48

#	ARTICLE	IF	CITATIONS
475	Hospitalizations associated with malignant neoplasia and in situ carcinoma in the anus and penis in men and women during a 5-year period (2009–2013) in Spain: An epidemiological study. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2292-2299.	1.4	3
476	Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. <i>Clinical Rheumatology</i> , 2017, 36, 2169-2178.	1.0	27
477	Vacunación en el adulto. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2017, 24, 9-42.	0.0	1
478	Primary care team- and clinic level factors affecting HPV vaccine uptake. <i>Vaccine</i> , 2017, 35, 4540-4547.	1.7	23
479	Knowledge and Behavioral Intention Related to HPV Vaccination Among Male College Students. <i>American Journal of Health Education</i> , 2017, 48, 320-330.	0.3	15
480	Human Papilloma Virus Vaccination and Incidence of Ocular Surface Squamous Neoplasia. <i>International Ophthalmology Clinics</i> , 2017, 57, 57-74.	0.3	7
481	4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years. <i>Pediatrics</i> , 2017, 140, .	1.0	51
483	Vaccine-Preventable Diseases and the Vaccines That Prevent Them. , 2017, , 101-168.		0
485	HPV-vaccinatie. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2017, 33, 29-40.	0.0	0
486	Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. <i>BMC Infectious Diseases</i> , 2017, 17, 249.	1.3	18
488	The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases. <i>Expert Review of Vaccines</i> , 2017, 16, 361-375.	2.0	16
489	Human papillomavirus (HPV): making the case for "Immisation for All™". <i>Oral Diseases</i> , 2017, 23, 726-730.	1.5	23
490	Country-specific HPV-related genital disease among men residing in Brazil, Mexico and The United States: The HIM study. <i>International Journal of Cancer</i> , 2017, 140, 337-345.	2.3	8
491	HPV Infection in Head and Neck Cancer. <i>Recent Results in Cancer Research</i> , 2017, , .	1.8	7
492	Vaccination Expectations in HNSCC. <i>Recent Results in Cancer Research</i> , 2017, 206, 257-267.	1.8	4
493	Epidemiology of Anal Canal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 9-15.	0.6	79
494	Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination. <i>Advances in Clinical Chemistry</i> , 2017, 81, 135-192.	1.8	13
495	Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 2455-2466.	1.1	31

#	ARTICLE	IF	CITATIONS
496	Prevalence of anogenital HPV infection, related disease and risk factors among HIV-infected men in inner-city Johannesburg, South Africa: baseline findings from a cohort study. <i>BMC Public Health</i> , 2017, 17, 425.	1.2	11
497	Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. <i>Cost Effectiveness and Resource Allocation</i> , 2017, 15, 11.	0.6	32
498	Cost-effectiveness of human papillomavirus vaccination in Germany. <i>Cost Effectiveness and Resource Allocation</i> , 2017, 15, 18.	0.6	24
499	Impact of HPV vaccination: health gains in the Italian female population. <i>Population Health Metrics</i> , 2017, 15, 36.	1.3	5
500	Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). <i>AIDS Research and Therapy</i> , 2017, 14, 34.	0.7	18
501	Incidence of anogenital warts in Liuzhou, south China: a comparison of data from a prospective study and from the national surveillance system. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-8.	3.0	8
503	Primary and secondary prevention of human papillomavirus-associated cancer: it's not all about women. <i>Microbiologia Medica</i> , 2017, 32, .	0.3	0
504	Penile squamous cell carcinoma: a review of the literature and case report treated with Mohs micrographic surgery. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 95-99.	0.5	23
505	Relationship between human papillomavirus and penile cancer—implications for prevention and treatment. <i>Translational Andrology and Urology</i> , 2017, 6, 791-802.	0.6	68
506	Chemoprevention Trials. , 2017, , .		1
507	Genital Wart and Human Papillomavirus Prevalence in Men in the United States From Penile Swabs: Results From National Health and Nutrition Examination Surveys. <i>Sexually Transmitted Diseases</i> , 2018, 45, 412-416.	0.8	17
508	High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus—Infected Individuals Older Than 26 Years: ACTG 5298. <i>Sexually Transmitted Diseases</i> , 2018, 45, 266-271.	0.8	17
509	Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges. <i>Vaccine</i> , 2018, 36, 2705-2711.	1.7	16
510	Risk Factors for Oral Human Papillomavirus Infection Among Young Men Who Have Sex With Men—2 Cities, United States, 2012—2014. <i>Sexually Transmitted Diseases</i> , 2018, 45, 660-665.	0.8	14
511	Vaccines and the Prevention of Dermatologic Diseases. , 2018, , 1109-1124.		0
512	Strengthening the case for gender-neutral and the nonavalent HPV vaccine. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 857-865.	0.8	10
513	2016 United Kingdom national guideline on the sexual health care of men who have sex with men. <i>International Journal of STD and AIDS</i> , 2018, , 095646241774689.	0.5	40
514	Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 63-74.	4.5	22

#	ARTICLE	IF	CITATIONS
515	Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015. <i>Epidemiology and Infection</i> , 2018, 146, 177-186.	1.0	15
516	Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence. <i>Pharmacoeconomics</i> , 2018, 36, 929-939.	1.7	3
517	Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication. <i>Gynecologic Oncology</i> , 2018, 149, 506-512.	0.6	12
518	Accelerating the Pace of Cancer Prevention- Right Now. <i>Cancer Prevention Research</i> , 2018, 11, 171-184.	0.7	21
519	HPV vaccination in male physicians: A survey of gynecologists and otolaryngology surgeons' attitudes towards vaccination in themselves and their patients. <i>Papillomavirus Research (Amsterdam, Tj ETQq0 0 0 rgBT /Overlock 10 of 50 577 T</i>		
520	Cancer Epidemiology: A Survey of Modifiable Risk Factors for Prevention and Survivorship. <i>American Journal of Lifestyle Medicine</i> , 2018, 12, 200-210.	0.8	60
521	Advances in Vaccine Technology. , 2018, , 45-58.		0
522	Review of cutaneous penile lesions. <i>Journal of Clinical Urology</i> , 2018, 11, 429-439.	0.1	0
523	HPV vaccine acceptability in high-risk Greek men. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 134-139.	1.4	10
524	Prevalence of Anal Human Papillomavirus Infection in Hungarian Men Who Have Sex with Men. <i>Pathology and Oncology Research</i> , 2018, 24, 671-677.	0.9	4
525	Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2018, 47, 42-58.	1.4	72
526	Active Immunization. , 2018, , 43-71.e4.		4
527	Who Will Benefit From Expanding HPV Vaccination Programs to Boys?. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky076.	1.4	7
528	Cervical Cancer: Screening, Vaccination, and Preventive Strategies. , 2018, , .		0
529	Cancers as Ecosystems: From Cells to Population. , 2018, , 278-278.		0
531	ASSESSMENT ON KNOWLEDGE REGARDING HUMAN PAPILOMAVIRUS VACCINATION AMONG MAHSA UNIVERSITY STUDENTS. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 61.	0.3	0
532	HIV-positive gay menâ€™s knowledge and perceptions of Human Papillomavirus (HPV) and HPV vaccination: A qualitative study. <i>PLoS ONE</i> , 2018, 13, e0207953.	1.1	32
533	Factors associated with Human Papilloma Virus (HPV) vaccine recommendation by physicians in Lebanon, a cross-sectional study. <i>Vaccine</i> , 2018, 36, 7562-7567.	1.7	19

#	ARTICLE	IF	CITATIONS
534	Knowledge and attitudes toward HPV infection and vaccination among immigrants and refugees in Italy. <i>Vaccine</i> , 2018, 36, 7536-7541.	1.7	26
535	Sociodemographic predictors of the Human Papillomavirus (HPV) and HPV Vaccine Knowledge and Awareness among Americans Who Use the Internet as Their Primary Source of Health Information. <i>Journal of Consumer Health on the Internet</i> , 2018, 22, 199-216.	0.2	7
536	Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men. <i>Future Microbiology</i> , 2018, 13, 1463-1472.	1.0	3
537	The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study. <i>PLoS ONE</i> , 2018, 13, e0202924.	1.1	7
538	Exploring Iranian women's perceptions and experiences regarding cervical cancer-preventive behaviors. <i>BMC Women's Health</i> , 2018, 18, 145.	0.8	14
540	Background paper for the recommendation of HPV vaccination for boys in Germany. <i>Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz</i> , 2018, 61, 1170-1186.	7.2	34
541	Clinical Trial Design in Immuno-Oncology. , 2018, , 151-173.		0
542	A Case of Human Papilloma Virus 31- and 68-Associated Metastatic Squamous Cell Carcinoma of the Cervix in a Healthy 28-Year-Old Woman. <i>Journal of Gynecologic Surgery</i> , 2018, 34, 159-163.	0.0	0
543	A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 6, 11-14.	4.5	10
545	Human papillomavirus (HPV) genotype distribution in penile carcinoma: Association with clinic pathological factors. <i>PLoS ONE</i> , 2018, 13, e0199557.	1.1	20
546	Human Papillomavirus Vaccines. , 2018, , 430-455.e10.		5
547	Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines. , 2018, , 619-643.e11.		7
548	HPV vaccination and the effects on rates of HPV-related cancers. <i>Current Problems in Cancer</i> , 2018, 42, 493-506.	1.0	62
549	Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. <i>BMC Medicine</i> , 2018, 16, 110.	2.3	106
550	Ethical issues related to human papillomavirus vaccination programs: an example from Bangladesh. <i>BMC Medical Ethics</i> , 2018, 19, 39.	1.0	7
551	Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction. <i>Journal of Adolescent Health</i> , 2018, 63, 43-49.	1.2	10
552	The Diagnostic and Therapeutic Challenge of Anal Intraepithelial Neoplasia. <i>Current Gastroenterology Reports</i> , 2018, 20, 38.	1.1	2
553	Characterization of Hemagglutinin Antigens on Influenza Virus and within Vaccines Using Electron Microscopy. <i>Vaccines</i> , 2018, 6, 31.	2.1	24

#	ARTICLE	IF	CITATIONS
554	Development of a human papillomavirus type 6/11 vaccine candidate for the prevention of condyloma acuminatum. <i>Vaccine</i> , 2018, 36, 4927-4934.	1.7	9
556	Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. <i>The Cochrane Library</i> , 2020, 2020, CD009069.	1.5	288
557	Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy. <i>Medical Oncology</i> , 2018, 35, 134.	1.2	4
558	Acceptability of HPV vaccines and associations with perceptions related to HPV and HPV vaccines among male baccalaureate students in Hong Kong. <i>PLoS ONE</i> , 2018, 13, e0198615.	1.1	31
559	Is there evidence for efficacy of human papillomavirus vaccination in solid organ transplant recipients?. <i>European Journal of Obstetrics and Gynecology and Reproductive Biology: X</i> , 2019, 4, 100015.	0.6	5
560	Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1660-1667.	1.1	127
561	Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label Study. <i>Japanese Journal of Infectious Diseases</i> , 2019, 72, 299-305.	0.5	3
562	Economic barriers, evidentiary gaps, and ethical conundrums: a qualitative study of physicians' challenges recommending HPV vaccination to older gay, bisexual, and other men who have sex with men. <i>International Journal for Equity in Health</i> , 2019, 18, 159.	1.5	17
563	<i>Trichomonas vaginalis</i> infection in southern Ghana: clinical signs associated with the infection. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 359-369.	0.7	4
564	Behavioral intention to perform risk compensation behaviors after receiving HPV vaccination among men who have sex with men in China. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1737-1744.	1.4	6
565	Viral metagenomics updated the prevalence of human papillomavirus types in anogenital warts. <i>Emerging Microbes and Infections</i> , 2019, 8, 1291-1299.	3.0	9
566	Dynamic factors affecting HPV-attributable fraction for head and neck cancers. <i>Current Opinion in Virology</i> , 2019, 39, 33-40.	2.6	21
567	Eradication of human papillomavirus and elimination of HPV-related diseases – scientific basis for global public health policies. <i>Expert Review of Vaccines</i> , 2019, 18, 153-160.	2.0	41
568	Facilitators and barriers for healthcare providers to recommend HPV vaccination to attendees of public sexually transmitted diseases clinics in Hong Kong, China. <i>PLoS ONE</i> , 2019, 14, e0209942.	1.1	4
569	Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1949-1961.	1.4	19
570	Addressing HPV vaccine myths: practical information for healthcare providers. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1628-1638.	1.4	51
571	Human Papillomavirus awareness and vaccine acceptability among men who have sex with men from mainland China. <i>Scientific Reports</i> , 2019, 9, 8763.	1.6	8
572	Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK. <i>BMC Infectious Diseases</i> , 2019, 19, 552.	1.3	38

#	ARTICLE	IF	CITATIONS
573	Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 361-368.	0.7	16
574	A significant portion of college students are not aware of HPV disease and HPV vaccine recommendations. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1760-1766.	1.4	49
575	Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. <i>Pharmaceutical Medicine</i> , 2019, 33, 269-289.	1.0	10
576	The Acceptability of HPV Vaccines and Perceptions of Vaccination against HPV among Physicians and Nurses in Hong Kong. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1700.	1.2	8
577	Update on HPV Vaccination. , 2019, , 443-450.		0
578	Human papillomavirus infection in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13590.	0.8	66
579	HPV-specific antibodies at the oral cavity up to 30 months after the start of vaccination with the quadrivalent HPV vaccine among mid-adult aged men. <i>Vaccine</i> , 2019, 37, 2864-2869.	1.7	12
580	HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1920-1928.	1.4	72
582	New Insights into the Role of Human Papillomavirus in Anal Cancer and Anal Wart Development. <i>Acta Cytologica</i> , 2019, 63, 118-123.	0.7	12
583	Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach. <i>PLoS Medicine</i> , 2019, 16, e1002756.	3.9	8
584	HPV Vaccine: Updates and Highlights. <i>Acta Cytologica</i> , 2019, 63, 159-168.	0.7	53
586	Multisite HPV infections in the United States (NHANES 2003-2014): An overview and synthesis. <i>Preventive Medicine</i> , 2019, 123, 288-298.	1.6	23
587	The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis. <i>Epidemiology and Infection</i> , 2019, 147, e156.	1.0	6
588	Position statement for the diagnosis and management of anogenital warts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1006-1019.	1.3	45
589	Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men. <i>Vaccine</i> , 2019, 37, 2502-2510.	1.7	13
590	Otolaryngologists and their role in vaccination for prevention of HPV associated head & neck cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1929-1934.	1.4	7
591	Human Papillomavirus and Genital Disease in Men: What We Have Learned from the HIM Study. <i>Acta Cytologica</i> , 2019, 63, 109-117.	0.7	22
592	Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study. <i>Vaccine</i> , 2019, 37, 1651-1658.	1.7	32

#	ARTICLE	IF	CITATIONS
593	Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. The Cochrane Library, 2019, 2019, .	1.5	65
594	Are Boys Ready for Human Papillomavirus Vaccine? A National Study of Boys in Malaysia. Sexually Transmitted Diseases, 2019, 46, 617-624.	0.8	1
596	Treating advanced penile cancer: where do we stand in 2019?. Current Opinion in Supportive and Palliative Care, 2019, 13, 249-254.	0.5	4
597	Prophylactic human papilloma virus vaccination in head and neck: indications and future perspectives. Current Opinion in Otolaryngology and Head and Neck Surgery, 2019, 27, 85-90.	0.8	7
598	Prevalence of HPV among HIV-negative women of child-bearing age in Lomé, Togo. Future Virology, 2019, 14, 783-790.	0.9	1
599	New directions in penile cancer. Lancet Oncology, The, 2019, 20, 16-17.	5.1	2
600	Pediatric Travel Vaccinations. , 2019, , 125-136.		3
601	Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender women. International Journal of STD and AIDS, 2019, 30, 154-162.	0.5	20
602	HPV vaccination acceptability among men who have sex with men in Urumqi, China. Human Vaccines and Immunotherapeutics, 2019, 15, 1005-1012.	1.4	17
603	Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2019, 219, 1016-1025.	1.9	51
604	Genital Wart Recurrence Among Men Residing in Brazil, Mexico, and the United States. Journal of Infectious Diseases, 2019, 219, 703-710.	1.9	11
605	Seroprevalence of Human Papillomavirus 6/11/16/18 Among Self-identified Gay/Bisexual Men Who Have Sex With Men, Men Who Have Sex With Women, and Females, United States, 2003-2010. Clinical Infectious Diseases, 2019, 69, 1011-1018.	2.9	8
606	Awareness and Knowledge Levels of 18-Year-Old and Older Individuals Regarding Human Papillomavirus (HPV) and HPV Vaccine in Hatay, Turkey. Journal of Cancer Education, 2019, 34, 234-241.	0.6	11
607	Disparities in Human Papillomavirus Vaccine Series Completion by Adolescent Males: A Retrospective Cohort Study. Academic Pediatrics, 2020, 20, 364-373.	1.0	9
608	HPV vaccine, Twitter, and gay, bisexual and other men who have sex with men. Health Promotion International, 2020, 35, 290-300.	0.9	2
609	Anal Cancer. , 2020, , 87-98.		0
610	Current Status and Future Perspectives of Molecular Prevention Strategies for Cervical Cancers. Indian Journal of Surgical Oncology, 2020, 11, 752-761.	0.3	2
611	Lifestyle and Cancer Prevention. , 2020, , 337-374.e12.		3



#	ARTICLE	IF	CITATIONS
612	Prevalence and Incidence of Human Papillomavirus Infection in Men Having Sex With Men Enrolled in a Pre-exposure Prophylaxis Study: A Sub-study of the Agence Nationale de Recherches sur le SIDA et les HÃ©patites Virales â€œIntervention PrÃ©ventive de lâ€™Exposition aux Risques avec et pour les hommes Gaysâ€ Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, 41-49.	2.9	8
613	Anal HPV Infection and HPV-Associated Disease. , 2020, , 195-204.		2
614	Oropharyngeal Human Papillomavirus and Head and Neck Cancer. , 2020, , 205-217.		0
615	Clinical Trials of Human Papillomavirus Vaccines. , 2020, , 299-325.		1
616	Twelve Years of Vaccine Registration and the Consequences. , 2020, , 349-361.		0
617	Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination. <i>Sexually Transmitted Diseases</i> , 2020, 47, 179-186.	0.8	2
618	Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2020, 10, 100203.	4.5	34
619	Human Papilloma Virus (HPV) status may impact treatment outcomes in patients with pre-cancerous penile lesions (an eUROGEN Study). <i>International Journal of Impotence Research</i> , 2021, 33, 620-626.	1.0	9
620	The management of penile intraepithelial neoplasia (PeIN): clinical and histological features and treatment of 345 patients and a review of the literature. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1047-1062.	1.1	24
621	Human Papillomavirus Vaccines: An Updated Review. <i>Vaccines</i> , 2020, 8, 391.	2.1	130
622	Penile cancer: a Brazilian consensus statement for low- and middle-income countries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3281-3296.	1.2	9
623	Human Papillomavirus, Herpes Zoster, and Hepatitis B Vaccinations in Immunocompromised Patients: An Update for Pharmacists. <i>Journal of Pharmacy Practice</i> , 2020, 34, 089719002095826.	0.5	1
625	Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1001-1046.	1.3	7
626	Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 579-607.	2.0	11
627	Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV): design and methods for a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e035113.	0.8	5
628	Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. <i>BMJ Evidence-Based Medicine</i> , 2020, 25, 213-219.	1.7	7
629	Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland. <i>BMC Public Health</i> , 2020, 20, 671.	1.2	8
630	The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis. <i>BMC Public Health</i> , 2020, 20, 691.	1.2	21

#	ARTICLE	IF	CITATIONS
631	Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016–2018. <i>Journal of Infectious Diseases</i> , 2020, 222, 2052-2060.	1.9	26
632	Review of Evidence and Recommendation for Human Papillomavirus (HPV) Vaccination of Canadian Males Over the Age of 26 Years. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 285-291.	0.6	4
633	HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination. <i>Vaccine</i> , 2020, 38, 3321-3329.	1.7	11
634	HPV vaccination and cancer prevention. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 109-124.	1.4	51
635	The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. <i>Frontiers in Immunology</i> , 2020, 11, 188.	2.2	93
636	Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. <i>Vaccine</i> , 2020, 38, 4687-4694.	1.7	12
637	HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). <i>Vaccines</i> , 2020, 8, 354.	2.1	21
638	Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches. <i>BMC Infectious Diseases</i> , 2020, 20, 482.	1.3	3
639	Binge drinking, HIV/HPV co-infection risk, and HIV testing: Factors associated with HPV vaccination among young adults in the United States. <i>Preventive Medicine</i> , 2020, 134, 106023.	1.6	4
640	Anal human papillomavirus among men who have sex with men in three metropolitan cities in southern China: implications for HPV vaccination. <i>Vaccine</i> , 2020, 38, 2849-2858.	1.7	12
641	Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications. <i>Systematic Reviews</i> , 2020, 9, 42.	2.5	3
643	Misinformation, Gendered Perceptions, and Low Healthcare Provider Communication Around HPV and the HPV Vaccine Among Young Sexual Minority Men in New York City: The P18 Cohort Study. <i>Journal of Community Health</i> , 2020, 45, 702-711.	1.9	19
644	Development of a sensitive and specific nanoparticle-assisted PCR assay for detecting HPV16 and HPV18 DNA. <i>Journal of Medical Virology</i> , 2020, 92, 3793-3798.	2.5	9
645	Sponsorship bias in clinical trials: growing menace or dawning realisation?. <i>Journal of the Royal Society of Medicine</i> , 2020, 113, 148-157.	1.1	15
646	The European response to the WHO call to eliminate cervical cancer as a public health problem. <i>International Journal of Cancer</i> , 2021, 148, 277-284.	2.3	52
647	Awareness, knowledge, social norms, and vaccination intentions among Khmer mother-daughter pairs. <i>Ethnicity and Health</i> , 2021, 26, 379-391.	1.5	5
648	How to recover lost vaccine acceptance? A multi-center survey on HPV vaccine acceptance in Japan. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 445-449.	0.8	15
649	Penile cancer: potential target for immunotherapy?. <i>World Journal of Urology</i> , 2021, 39, 1405-1411.	1.2	19

#	ARTICLE	IF	CITATIONS
650	Effect of an educational intervention on human papillomavirus (HPV) knowledge and attitudes towards HPV vaccines among healthcare workers (HCWs) in Western China. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 443-450.	1.4	16
652	Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. <i>Vaccine</i> , 2021, 39, 438-446.	1.7	16
653	Health consciousness and cervical cancer screening rates in HPV-unvaccinated girls: comparison from HPV-recommended and HPV-recommendation-suspended program periods. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1068-1072.	1.4	5
654	Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study. <i>Vaccine</i> , 2021, 39, 760-766.	1.7	2
655	The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value. <i>PLoS ONE</i> , 2021, 16, e0244722.	1.1	5
656	Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e94.	1.0	3
657	DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses. <i>Emerging Microbes and Infections</i> , 2021, 10, 833-841.	3.0	6
658	Role of human papillomavirus 6 & 11 in condyomata acuminata in Indian patients. <i>Indian Journal of Pathology and Microbiology</i> , 2021, 64, 532.	0.1	0
659	Cervical Cancer Screening. , 2021, , 151-159.		0
660	S3-Leitlinie Analkarzinom. <i>Coloproctology</i> , 2021, 43, 1-2.	0.3	1
661	Two Web-Based and Theory-Based Interventions With and Without Brief Motivational Interviewing in the Promotion of Human Papillomavirus Vaccination Among Chinese Men Who Have Sex With Men: Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2021, 23, e21465.	2.1	9
662	Penile cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 11.	18.1	93
664	A 10-year systematic review of theory-driven approaches to increasing catch-up HPV vaccination rates among young adult males in colleges/university settings. <i>Journal of American College Health</i> , 2022, 70, 2535-2547.	0.8	4
665	Elimination of HPV-associated oropharyngeal cancers in Nordic countries. <i>Preventive Medicine</i> , 2021, 144, 106445.	1.6	9
666	Improving adolescent human papillomavirus (HPV) immunization uptake in school-based health centers through awareness campaigns. <i>Vaccine</i> , 2021, 39, 1765-1772.	1.7	4
667	Sex difference in the immunogenicity of the quadrivalent Human Papilloma Virus vaccine: Systematic review and meta-analysis. <i>Vaccine</i> , 2021, 39, 1680-1686.	1.7	8
668	Papillomavirus humains : d'Étude et Prévention. <i>Revue Francophone Des Laboratoires</i> , 2021, 2021, 60-70.	0.0	0
669	Risk Factors for the Development of Malignant Tumors of the Head and Neck. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2021, 20, 92-99.	0.2	1

#	ARTICLE	IF	CITATIONS
670	Epidemiological and evolutionary consequences of periodicity in treatment coverage. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2021, 288, 20203007.	1.2	8
671	Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?. <i>Preventive Medicine</i> , 2021, 144, 106321.	1.6	12
672	The Risk of Anal Carcinoma After Anogenital Warts in Adults Living With HIV. <i>JAMA Dermatology</i> , 2021, 157, 283.	2.0	13
673	Human papillomavirus prevalence among men who have sex with men in China: a systematic review and meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1357-1367.	1.3	17
674	Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. <i>PLoS Medicine</i> , 2021, 18, e1003534.	3.9	30
675	Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. <i>JAMA Network Open</i> , 2021, 4, e214340.	2.8	15
676	The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy. <i>Current Medicinal Chemistry</i> , 2021, 28, 893-909.	1.2	23
677	Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium. <i>Frontiers in Pharmacology</i> , 2021, 12, 628434.	1.6	5
678	<i>Chlamydia trachomatis</i> vaccines for genital infections: where are we and how far is there to go?. <i>Expert Review of Vaccines</i> , 2021, 20, 421-435.	2.0	26
679	The Synthesis of Main Capsid Protein of Anogenital Type HPV6 L1 in Plant Expression System on the Basis of Tomato Fruits. <i>Doklady Biochemistry and Biophysics</i> , 2021, 498, 193-198.	0.3	2
680	Prevalence of Genital Human Papillomavirus by Age and Race/Ethnicity Among Males. <i>Clinical Infectious Diseases</i> , 2021, 73, 1625-1633.	2.9	5
681	High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex With Men Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, 1388-1396.	2.9	17
682	Treatment Options and Outcomes for Men with Penile Intraepithelial Neoplasia: A Systematic Review. <i>European Urology Focus</i> , 2022, 8, 829-832.	1.6	12
683	HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study. <i>Vaccines</i> , 2021, 9, 643.	2.1	4
685	Genital Human Papillomavirus Prevalence and Genotyping Among Males in Putuo District of Shanghai, China 2015-2019. <i>Medical Science Monitor</i> , 2021, 27, e932093.	0.5	2
686	Anal cancer screening and prevention: a review for dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1622-1627.	1.3	6
687	Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. <i>Vaccine</i> , 2021, 39, 3696-3716.	1.7	26
689	Get Vaccinated for Loved Ones: Effects of Self-Other Appeal and Message Framing in Promoting HPV Vaccination among Heterosexual Young Men. <i>Health Communication</i> , 2023, 38, 381-393.	1.8	6

#	ARTICLE	IF	CITATIONS
690	Effectiveness of Human Papillomavirus (HPV) Vaccination Against Penile HPV Infection in Men Who Have Sex With Men and Transgender Women. <i>Journal of Infectious Diseases</i> , 2022, 225, 422-430.	1.9	11
691	Risk-Benefit Analysis of the 9-Valent HPV Vaccination for Adolescent Boys from an Individual Perspective. <i>Japanese Journal of Infectious Diseases</i> , 2022, 75, 114-120.	0.5	1
692	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
693	Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial. <i>Clinical Infectious Diseases</i> , 2022, 74, 1247-1256.	2.9	8
694	Human papillomavirus-related inequalities in disease prevention and the impact on racial, ethnic, sexual, and gender minorities. <i>Pediatric Dermatology</i> , 2021, 38, 170-173.	0.5	1
695	Impact of Sexual Activity on the Risk of Male Genital Tumors: A Systematic Review of the Literature. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8500.	1.2	32
696	Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection. <i>Viruses</i> , 2021, 13, 1548.	1.5	1
697	Increases in HPV-16/18 antibody avidity and HPV-specific memory B-cell response in mid-adult aged men post-dose three of the quadrivalent HPV vaccine. <i>Vaccine</i> , 2021, 39, 5295-5301.	1.7	1
698	HPV vaccine for men: Where to? (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1266.	0.8	5
699	Human Papillomavirus Vaccines. <i>Journal of Infectious Diseases</i> , 2021, 224, S367-S378.	1.9	57
700	Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. <i>Annals of Oncology</i> , 2021, 32, 1087-1100.	0.6	100
701	Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. <i>JAMA Network Open</i> , 2021, 4, e2124502.	2.8	58
702	Challenges of Human Papillomavirus Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. , 2021, , 833-858.		0
703	Environmental and Genetic Factors Contributing to Bladder Carcinogenesis. , 2021, , 13-44.		1
704	Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal HPV-related HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years. <i>Viruses</i> , 2021, 13, 144.	1.5	16
705	Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956-2015. <i>International Journal of Cancer</i> , 2018, 142, 1586-1593.	2.3	58
706	Human Papilloma Virus Vaccines. , 2015, , 271-289.		1
707	Control of HPV Infection and Related Cancer Through Vaccination. <i>Recent Results in Cancer Research</i> , 2014, 193, 149-171.	1.8	31

#	ARTICLE	IF	CITATIONS
708	Examples of Novel Registered Prophylactic Vaccines, HPV, and JEV. , 2012, , 233-286.		1
710	An Update to Changing Patterns of Anal Carcinoma in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 887-897.	0.6	5
711	Human Papillomaviruses. , 0, , 1783-1802.		1
712	HPV16 and HPV18 seropositivity and DNA detection among men who have sex with men: a cross-sectional study conducted in a sexual health clinic in London. Sexually Transmitted Infections, 2021, 97, 382-386.	0.8	2
713	Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis. International Journal of STD and AIDS, 2020, 31, 606-612.	0.5	13
714	Capsomer Vaccines Protect Mice from Vaginal Challenge with Human Papillomavirus. PLoS ONE, 2011, 6, e27141.	1.1	13
715	Prevalence of DNA-HPV in Male Sexual Partners of HPV-Infected Women and Concordance of Viral Types in Infected Couples. PLoS ONE, 2012, 7, e40988.	1.1	37
716	A Cross-Sectional Study to Assess HPV Knowledge and HPV Vaccine Acceptability in Mali. PLoS ONE, 2013, 8, e56402.	1.1	52
717	Acceptability of HPV Vaccines and Associations with Perceptions Related to HPV and HPV Vaccines Among Men Who Have Sex with Men in Hong Kong. PLoS ONE, 2013, 8, e57204.	1.1	34
718	Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. PLoS ONE, 2013, 8, e68329.	1.1	387
719	Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of Gardasilâ„¢ in Adult Women. PLoS ONE, 2013, 8, e83431.	1.1	67
720	The economic burden of human papillomavirus-related precancers and cancers in Sweden. PLoS ONE, 2017, 12, e0179520.	1.1	16
721	Primary care pediatriciansâ€™ attitudes and practice towards HPV vaccination: A nationwide survey in Italy. PLoS ONE, 2018, 13, e0194920.	1.1	57
722	Update on Human Papillomavirus (HPV) Vaccines. Canada Communicable Disease Report, 2012, 38, 1-62.	0.6	27
723	Quality Improvement Project on Ob/Gyn Ambulatory Clinic HPV Vaccination in a Tertiary Community Hospital. Obstetrics & Gynecology International Journal, 2015, 3, .	0.0	1
725	Should routine neonatal circumcision be a policy to prevent penile cancer?   Opinion: No. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 10-12.	0.7	3
726	VacinaÃo contra papilomavÃrus humano. Einstein (Sao Paulo, Brazil), 2013, 11, 547-549.	0.3	8
727	Sexually Transmitted Infections: Impact and Cost-Effectiveness of Prevention. , 2017, , 203-232.		26

#	ARTICLE	IF	CITATIONS
728	Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis. <i>Salud Publica De Mexico</i> , 2017, 59, 84.	0.1	11
729	Using Facebook to Recruit Young Australian Men Into a Cross-Sectional Human Papillomavirus Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e389.	2.1	12
730	Targeted Facebook Advertising is a Novel and Effective Method of Recruiting Participants into a Human Papillomavirus Vaccine Effectiveness Study. <i>JMIR Research Protocols</i> , 2016, 5, e154.	0.5	35
731	Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016. <i>Eurosurveillance</i> , 2019, 24, .	3.9	26
732	Anal human papillomavirus and HIV: A cross-sectional study among men who have sex with men in Moscow, Russia, 2012â€“2013. <i>Eurosurveillance</i> , 2015, 20, .	3.9	10
733	Assessing the Population Impact of Published Intervention Studies. <i>NAM Perspectives</i> , 2015, 5, .	1.3	1
734	Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. <i>GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery</i> , 2012, 11, Doc09.	0.8	54
735	Penile carcinoma and HPV infection (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 91-96.	0.8	22
736	Human papillomavirus infection and disease in men: Impact of HIV. <i>Southern African Journal of HIV Medicine</i> , 2013, 14, 183-188.	0.3	4
737	Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?. <i>Annals of Medical and Health Sciences Research</i> , 2013, 3, 306.	0.8	15
738	Knowledge and Behavior of University Students toward Human Papillomavirus and Vaccination. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2019, 6, 300.	0.7	28
739	Exploring Complicity of Cervical Cancer Screening in Malawi: The Interplay of Behavioral, Cultural, and Societal Influences. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2020, 7, 18-27.	0.7	12
740	Cervical HPV Infection in Indian Women: Screening and Immunization as Preventive Strategies. <i>MGM Journal of Medical Sciences</i> , 2014, 1, 65-75.	0.1	1
741	Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men. <i>Contemporary Clinical Trials</i> , 2022, 115, 106592.	0.8	15
745	Adolescent Rape. , 2011, , 702-705.e1.		1
747	Dynamics of genital human papillomavirus (HPV) infections among males eventually being uncovered. <i>Asian Journal of Andrology</i> , 2011, 13, 361-362.	0.8	0
748	Immunization in Adolescents: Past, Present and Future. <i>The Open Vaccine Journal</i> , 2011, 4, 3-12.	0.6	2
750	Management and Prevention of Infectious Diseases in Inflammatory Bowel Disease Patients. , 2012, , 679-700.		0

#	ARTICLE	IF	CITATIONS
751	Papillomavirus. , 2012, , 2121-2125.		2
752	Active Immunization. , 2012, , 44-68.e6.		1
753	Current Insight into Anti-HPV Immune Responses and Lessons for Prophylactic and Therapeutic Vaccines. , 0, , .		0
754	Patterns and Trends in HPV-Related Oral Cancer and Other HPV-Associated Cancers. , 2012, , 107-130.		0
755	Impact of human papillomavirus vaccination on anal cancer incidence in French women. Journal of Public Health and Epidemiology, 2012, 4, .	0.1	0
757	Prophylactic Vaccines Against HPV Infection. Journal of Clinical Otolaryngology, 2012, 23, 32-37.	0.1	0
758	Human Papillomavirus Vaccine and Prevention of Human Papillomavirus-Associated Disease in the USA. , 2013, , 383-400.		0
759	Capturing and Deciphering the Molecular Signatures of Head and Neck Cancer. , 2013, , 97-130.		0
761	Pediatric Travel Vaccinations. , 2013, , 125-133.		1
762	Sexuell ¼bertragene Infektionen (STI). Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 546-559.	0.0	0
763	Anal Cancer. , 2014, , 273-288.		0
764	Sexually transmitted diseases and the anorectum. , 2014, , 253-268.		0
765	A Study on the Level of Health Beliefs and Knowledge about Human Papilloma Virus(HPV) Vaccination among Health College Students. Journal of Fisheries and Marine Sciences Education, 2014, 26, 345-356.	0.0	3
766	Sub-acute toxicity study in female ICR mice following repetitive intramuscular injection of cervical cancer vaccine. Environmental Health and Toxicology, 2014, 29, e2014024.	1.8	0
767	Sub-acute toxicity study in female ICR mice following repetitive intramuscular injection of cervical cancer vaccines. Environmental Health and Toxicology, 0, 29, e2014024.	1.8	0
768	Human Papillomaviruses. , 2015, , 15-43.		0
769	Boys Get the Cervical Cancer Virus? Understanding How Parents of Boys Feel About the HPV Vaccine. SSRN Electronic Journal, 0, , .	0.4	0
770	Anal intraepitelial neoplasia: A narrative review. Revista Espanola De Enfermedades Digestivas, 2015, , .	0.1	7



#	ARTICLE	IF	CITATIONS
771	The Role of Vaccines for HPV-Related Head and Neck Cancers. Head and Neck Cancer Clinics, 2015, , 99-110.	0.0	1
773	Future Directions and Clinical Trials in Penile Cancer. , 2016, , 311-324.		0
774	Differing Intentions and Behaviours about the HPV Vaccine among Midwestern Undergraduate Men and Women. Journal of Vaccines & Vaccination, 2016, 07, .	0.3	0
775	Impact of Global HPV Vaccination for Male Genital Disease. , 2016, , 31-36.		0
776	Diagnostic Applications of Nuclear Medicine: Vulvar Cancer. , 2016, , 1-21.		0
777	Assessing the Changing Oral and Pharyngeal Cancer Demographic in the United States. , 2016, , 3-19.		0
778	THE SOCIODEMOGRAPHIC CHARACTERISTICS, CLINICAL PROFILE AND TREATMENT RECORDS OF ANOGENITAL WARTS IN EASTERN UTTAR PRADESH- A RETROSPECTIVE EVALUATION FROM TREATMENT RECORDS AT A TERTIARY CENTRE. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 491-495.	0.1	0
779	Present views on genital warts: Possibilities for treatment and prevention. Russian Bulletin of Obstetrician-Gynecologist, 2017, 17, 109.	0.0	2
780	Prevention of Complications from Human Papillomavirus Infection in the HIV-Infected Individual. , 2017, , 141-163.		0
781	Anal Dysplasia/Cancer: Management of Patients with AIN 3. Difficult Decisions in Surgery: an Evidence-based Approach, 2017, , 255-265.	0.0	1
782	Diagnostic Applications of Nuclear Medicine: Vulvar Cancer. , 2017, , 959-978.		0
783	Human Papillomavirus Vaccination: Making Sense of the Public Controversy. , 2018, , 59-94.		0
784	Human Papillomavirus and Head and Neck Cancer. , 2018, , 349-364.		0
785	Risky Behaviours. , 2018, , 55-89.		0
786	Anal Cancer. , 2018, , 22-32.		0
787	The Role of Vaccination in the Prevention of Head and Neck Cancer. , 2018, , 3-13.		0
789	HPV-Impfung (1): Freiwilliges Impfangebot an Grundschulen ist erfolgreich. Deutsches A&#x0308;rztblatt International, 0, , .	0.6	1
790	Universal HPV Vaccination â€“ a Global Prerogative. International Journal of Men's Social and Community Health, 2018, 1, e14-e22.	0.2	0

#	ARTICLE	IF	CITATIONS
791	Anal Intraepitheial Neoplasia. , 2019, , 347-357.		0
792	Approach and Management of Cervical Cancer. , 2019, , 491-549.		0
793	Human papillomavirus vaccination: review of the current evidence. <i>Mucosa</i> , 2019, 2, 86-94.	0.3	1
794	Burden of Genital Warts in Colombia: An Observational Study. <i>Jornal Brasileiro De DoenÇas Sexualmente Transmissíveis</i> , 0, 32, .	0.1	0
795	Human Papillomavirus (HPV). , 2020, , 1113-1115.		0
796	Achievements and Prospects of Vaccination against Human Papillomavirus Infection and Associated Diseases. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2020, 19, 110-118.	0.2	1
799	HPV vaccine development after more than ten years approval. <i>Majalah Obstetri Dan Ginekologi</i> , 2020, 28, 39.	0.1	0
800	PAPILLOMAVIRAL CARCINOGENESIS. MAJOR ACHIEVEMENTS AND CERTAIN CHALLENGES PART 2. HPV-ASSOCIATED CANCERS IN RUSSIA. PREVENTIVE HPV VACCINES. , 2020, 19, 31-38.	0.3	3
801	Penile Cancer. , 2021, , 295-302.		0
802	Sexually Transmitted Infections and Sexual Healthcare of Homeless and Street-Involved Youth. , 2020, , 243-270.		1
803	Performance of human papillomavirus DNA detection in residual specimens taken for Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid amplification testing in men who have sex with men. <i>Sexually Transmitted Infections</i> , 2021, 97, 541-546.	0.8	5
804	A New Strategy for Elimination of Human Papilloma Virus-related Disease after Human Papillomavirus Vaccines Introduction. <i>Urogenital Tract Infection</i> , 2020, 15, 63-70.	0.1	1
805	Intrauterine device and cervical cancer. <i>Majalah Obstetri Dan Ginekologi</i> , 2020, 28, 140.	0.1	0
807	Challenges of Human Papillomavirus Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. , 2020, , 1-26.		0
808	Immunotherapeutic approaches in HNSCC. , 2020, , 117-142.		1
809	Prinzipien der primären Prävention von Krebserkrankungen. <i>Springer Reference Medizin</i> , 2020, , 1-14.	0.0	0
812	Achievements and Prospects of Vaccination against Human Papillomavirus Infection and Associated Diseases. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2020, 19, 110-118.	0.2	0
814	HPV awareness and willingness to HPV vaccination among high-risk men attending an STI clinic in Puerto Rico. <i>Puerto Rico Health Sciences Journal</i> , 2012, 31, 227-31.	0.2	10

#	ARTICLE	IF	CITATIONS
816	Anorectal human papillomavirus: current concepts. <i>Yale Journal of Biology and Medicine</i> , 2014, 87, 537-47.	0.2	13
817	Human papillomavirus vaccination for boys. <i>Canadian Family Physician</i> , 2015, 61, 43-6.	0.1	12
818	HPV vaccine for cancer and wart prevention. <i>Canadian Family Physician</i> , 2015, 61, 50.	0.1	3
819	Human papillomavirus seroprevalence among men entering military service and seroincidence after ten years of service. <i>Msmr</i> , 2013, 20, 21-4.	0.4	4
820	HPV related diseases in males: a heavy vaccine-preventable burden. <i>Journal of Preventive Medicine and Hygiene</i> , 2013, 54, 61-70.	0.9	6
821	Update on the new 9-valent vaccine for human papillomavirus prevention. <i>Canadian Family Physician</i> , 2016, 62, 399-402.	0.1	28
822	Universal proposal strategies of anti-HPV vaccination for adolescents: comparative analysis between school-based and clinic immunization programs. <i>Journal of Preventive Medicine and Hygiene</i> , 2017, 58, E225-E230.	0.9	9
823	Sexually-transmitted infections: what is the true prevalence? A cross-sectional online survey of men who have sex with men in the Veneto Region of Italy. <i>Journal of Preventive Medicine and Hygiene</i> , 2019, 60, E197-E202.	0.9	1
824	Should men be exempted from vaccination against human papillomavirus? Health disparities regarding HPV: the example of sexual minorities in Poland. <i>Journal of Preventive Medicine and Hygiene</i> , 2021, 62, E386-E391.	0.9	0
825	Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 38-48.	2.7	7
826	Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 413-425.	4.6	50
827	Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. <i>Vaccines</i> , 2021, 9, 1413.	2.1	77
829	PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?. <i>International Immunopharmacology</i> , 2022, 103, 108484.	1.7	2
830	Increasing HPV vaccination coverage to prevent oropharyngeal cancer: A cost-effectiveness analysis. <i>Tumour Virus Research</i> , 2022, 13, 200234.	1.5	4
831	HPV-assozierte Neoplasien: Wie die Impfprävention gefördert werden kann. , 0, , .		0
833	What influences parents to vaccinate (or not) their sons with the Human Papillomavirus (HPV) vaccine: an examination of HPV vaccine decision-making changes over time. <i>Journal of Psychosocial Oncology Research and Practice</i> , 2022, 4, e068.	0.2	1
834	Long-Term Effects of Human Papillomavirus Vaccination in Clinical Trials and Real-World Data: A Systematic Review. <i>Vaccines</i> , 2022, 10, 256.	2.1	4
835	Correlation between recurrence of anorectal condyloma acuminatum and human papilloma virus subtype. <i>Genes and Genomics</i> , 2022, 44, 389-394.	0.5	3

#	ARTICLE	IF	CITATIONS
836	HPV-mediated Cervical Cancer: A Systematic Review on Immunological Basis, Molecular Biology, and Immune Evasion Mechanisms. <i>Current Drug Targets</i> , 2022, 23, 782-801.	1.0	3
837	Vaccination against Human Papillomavirus (HPV) in Vulnerable Populations. <i>Sexual Minorities.</i> , 0, , .		0
840	Disparities in cancer screenings for sexual and gender minorities. <i>Current Problems in Cancer</i> , 2022, 46, 100858.	1.0	9
841	Gene methylation of CADM1 and MAL identified as a biomarker of high grade anal intraepithelial neoplasia. <i>Scientific Reports</i> , 2022, 12, 3565.	1.6	9
843	Asian guidelines for condyloma acuminatum. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 845-852.	0.8	20
844	Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	1.4	22
845	Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom. <i>Vaccine</i> , 2022, 40, 2173-2183.	1.7	4
846	Factors Affecting Human Papillomavirus Vaccination in Men: Systematic Review. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e34070.	1.2	9
847	Human papillomavirus vaccination coverage among young, gay, bisexual, and other men who have sex with men and transgender women " 3 U.S. cities, 2016"2018. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5407-5412.	1.4	7
848	Virus del papiloma humano (VPH): microbiologÃa, relaciÃ³n con el cÃ¡ncer de pene y caracterÃsticas de la vacuna. <i>Revista Mexicana De Urologia</i> , 2020, 80, 1-10.	0.0	1
849	Human Papillomavirus (HPV) Entry Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 223-239.	0.8	0
850	Immunoglobulin A Deficiency and Squamous Cell Carcinoma With a Rare Presentation as Anal Cancer.. <i>Journal of Medical Cases</i> , 2022, 13, 26-30.	0.4	0
853	Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada. <i>Vaccine</i> , 2022, 40, 3690-3700.	1.7	3
854	Investigation of the diversity of human papillomavirus 16 variants and L1 antigenic regions relevant for the prevention of human papillomavirus-related oropharyngeal cancer in Japan. <i>Auris Nasus Larynx</i> , 2022, , .	0.5	0
855	HPV Vaccination: Does It Have a Role in Preventing Penile Cancer and Other Preneoplastic Lesions?. <i>Seminars in Oncology Nursing</i> , 2022, 38, 151284.	0.7	9
857	Viral Diseases of the Skin. , 2016, , 360-381.e3.		1
858	Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018. <i>Annals of Internal Medicine</i> , 2022, 175, 918-926.	2.0	20
860	Clinical Benefit of Vaccinating Male Against HPV-related Disease. <i>Korean Society for Head and Neck Oncology</i> , 2022, 38, 11-16.	0.1	0

#	ARTICLE	IF	CITATIONS
862	Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom. <i>Journal of Health Economics and Outcomes Research</i> , 2022, 9, .	0.6	0
863	Uptake of Human Papillomavirus Vaccination by HIV Status and HIV Pre-exposure Prophylaxis (PrEP) Care Engagement Among Young Sexual Minority Men 17-24 Years Old in the USA. <i>Sexuality Research and Social Policy</i> , 2022, 19, 1944-1953.	1.4	2
864	Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
865	Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom. <i>Journal of Health Economics and Outcomes Research</i> , 2022, 9, 140-150.	0.6	2
866	Factors Influencing Men's Attitudes toward HPV Vaccination in Males Included in the Chinese National Immunization Program. <i>Vaccines</i> , 2022, 10, 1054.	2.1	1
867	Reinfection of Nine-Valent Human Papillomavirus Vaccine Types Among HIV-Negative Men Who Have Sex With Men: A Prospective Cohort Study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
868	Factors contributing to missed opportunities for human papillomavirus vaccination among adolescents, ages 11 to 13, in Iowa. <i>Vaccine: X</i> , 2022, 11, 100192.	0.9	0
869	The Male Domain-Digital Game-Based Learning for Human Papillomavirus Vaccination Among Young Males. <i>Games for Health Journal</i> , 0, , .	1.1	0
870	Research progress of HPV vaccine for preventing damage from HPV infection. , 0, 8, 604-610.		0
871	The Epidemiology of Penile Cancer. , 0, , 131-139.		4
872	HPV and head and neck cancers: Towards early diagnosis and prevention. <i>Tumour Virus Research</i> , 2022, 14, 200245.	1.5	15
873	The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan. <i>Value in Health Regional Issues</i> , 2022, 32, 79-87.	0.5	2
874	An overview of HPV: Causes, symptoms, and clinical manifestations. , 2022, , 1-19.		0
875	Diagnostic Applications of Nuclear Medicine: Vulvar Cancer. , 2022, , 1115-1138.		0
876	Healthcare Provider Recommendations and Observed Changes in HPV Vaccination Acceptance during the COVID-19 Pandemic. <i>Vaccines</i> , 2022, 10, 1515.	2.1	2
877	Social contextual factors interact with masculinity to influence college men's HPV vaccination intentions: The role of descriptive norms, prototypes, and physician gender. <i>Journal of Behavioral Medicine</i> , 0, , .	1.1	0
878	An overview of implementing an evidence based program to increase HPV vaccination in HIV community clinics. <i>BMC Public Health</i> , 2022, 22, .	1.2	0
879	Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6

#	ARTICLE	IF	CITATIONS
880	HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage. <i>Cancer Treatment Reviews</i> , 2022, 111, 102467.	3.4	9
881	Survey of pediatricians concerning the human papillomavirus vaccine in Japan: Positive attitudes toward vaccination during the period of proactive recommendation being withheld. <i>Human Vaccines and Immunotherapeutics</i> , 0, , .	1.4	1
883	Factors affecting children's HPV vaccination in Austria: Evidence from a parent survey. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	2
884	Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	5
885	Healthcare providers' practice protocols, strategies, and needed tools to address parental HPV vaccine hesitancy: An exploratory study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	4
886	Active Immunization. , 2023, , 44-72.e5.		0
887	Primary prevention of cervical cancer in women: Human papillomavirus vaccine. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2023, 281, 29-31.	0.5	0
888	Sodium Valproate-induced Eosinophilic Exudative Pleural Effusion. <i>Indian Journal of Clinical Medicine</i> , 2022, 12, 39-41.	0.2	1
889	Prevalence and concordance of oral and genital HPV by sexual orientation among US men. <i>JNCI Cancer Spectrum</i> , 2023, 7, .	1.4	6
890	Updates on HPV Vaccination. <i>Diagnostics</i> , 2023, 13, 243.	1.3	14
891	What Are the Barriers to Human Papillomavirus Vaccination for Male in South Korea?. <i>Urogenital Tract Infection</i> , 2022, 17, 53-60.	0.1	0
892	Upper age-limits for US male HPV-vaccination for oropharyngeal cancer prevention: A microsimulation-based modeling study. <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	2
893	Cancer Prevention Begins in Middle School: The Personal Advantages of HPV Immunization in Males. <i>NASN School Nurse (Print)</i> , 0, , 1942602X2211511.	0.4	0
894	Healthcare Provider's Perceived Self-Efficacy in HPV Vaccination Hesitancy Counseling and HPV Vaccination Acceptance. <i>Vaccines</i> , 2023, 11, 300.	2.1	2
895	Parent-reported Barriers and Parental Beliefs Associated with Intentions to Obtain HPV Vaccination for Children in a Primary care Patient Population in Minnesota, USA. <i>Journal of Community Health</i> , 2023, 48, 678-686.	1.9	5
896	The impact of human papilloma virus on human reproductive health and the effect on male infertility: An updated review. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4
897	Awareness and knowledge regarding human papilloma virus vaccine among medical students. <i>Journal of Dr NTR University of Health Sciences</i> , 2022, 11, 220.	0.0	0
898	Factors related to human papillomavirus vaccine uptake and intentions among adults aged 18-26 and 27-45 years in the United States: A cross-sectional study. <i>Cancer</i> , 2023, 129, 1237-1252.	2.0	3

#	ARTICLE	IF	CITATIONS
899	Impact of nucleic acid extraction procedures on human papillomavirus (HPV) detection and genotyping. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
900	Human Papillomavirus: The Fundamentals of HPV for Oral Health Care Providers. <i>Journal of the California Dental Association</i> , 2013, 41, 349-355.	0.0	5
902	Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. <i>Cancers</i> , 2023, 15, 1701.	1.7	4
903	Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	1
904	Human papillomavirus (HPV) vaccination: a call for action in Italy. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 1132-1139.	1.2	6
905	Human Papillomaviruses in Adolescents: Knowledge, Attitudes, and Practices of Pharmacists Regarding Virus and Vaccination in France. <i>Viruses</i> , 2023, 15, 778.	1.5	2
906	Anogenital Condyloma and Other Sexually Transmitted Diseases. , 2013, , 186-204.		0
907	Vaccines and the Prevention of Dermatologic Diseases. , 2023, , 1501-1520.		0
908	Definition and rationale for placebo composition: Cross-sectional analysis of randomized trials and protocols published in high-impact medical journals. <i>Clinical Trials</i> , 0, , 174077452311677.	0.7	0
909	An Integrative Approach, by Using a Bi-Digital O-Ring Test (BDORT), Advanced Bioinformatics, and Clinical Testing for the Development of New Effective Treatment of Infections Caused by Human Papillomaviruses (HPV). <i>Acupuncture and Electro-Therapeutics Research</i> , 2023, , .	0.0	0
910	Human Papillomavirus Infections and Increased Risk of Incident Osteoporosis: A Nationwide Population-Based Cohort Study. <i>Viruses</i> , 2023, 15, 1021.	1.5	0
922	Epidemiology and Prevention. I-1. Epidemiology and Risk Factors. , 2023, , 289-292.		0
924	Human Papillomavirus Vaccines. , 2023, , 484-513.e11.		0
930	Premalignant Penile Lesions. <i>Management of Urology</i> , 2023, , 65-81.	0.0	0